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Preface 
“As to the Soviet satellite, we congratulate Soviet scientists upon 
putting a satellite into orbit.” 
-Dwight D. Eisenhower, Oct. 9, 19571 
 
On October 4, 1957, the Union of Soviet Socialist Republics became 
the first world power to successfully put a human-made satellite into 
Earth’s orbit.2 The Sputnik I satellite was modest by today’s standards: 
it was less than two feet in diameter, weighed less than 200 pounds,3 
and was only capable of emitting pulsed radio signals.4 By many 
accounts, it was little more than a large beach ball floating around and 
around the Earth.5 Nevertheless, the propaganda value of the Soviet 
achievement in the burgeoning Cold War was significant and 
unmistakable.6 The Space Race had begun, and the Soviets had won 
the first leg of it. The American response was swift. On January 31, 
1958—119 days after the Sputnik I launch—Explorer-I successfully 
 
1. Dwight D. Eisenhower, President of the United States, Statement by the 
President Summarizing Facts in the Development of an Earth Satellite by 
the United States (Oct. 9, 1957), available at https://www.eisenhower.
archives.gov/research/online_documents/sputnik/10_9_57.pdf. 
2. Sputnik 1, NASA, https://www.nasa.gov/multimedia/imagegallery/im
age_feature_924.html (last visited Feb. 5, 2018). 
3. Sputnik and The Dawn of the Space Age, NASA, https://history.
nasa.gov/sputnik/ (last visited Feb. 5, 2018). 
4. Paul Dickson, Sputnick’s Impact on America, PBS (Nov. 11, 2017), 
http://www.pbs.org/wgbh/nova/space/sputnik-impact-on-america.html, 
(“Listen now, for the sound that forevermore separates the old from the 
new,” reported the NBC radio network announcer. Id.). 
5. Id. 
6. Id. (“No event since Pearl Harbor set off such repercussions in public life,” 
WALTER A. MCDOUGALL, THE HEAVENS AND THE EARTH: A POLITICAL 
HISTORY OF THE SPACE AGE (Johns Hopkins University Press 1997)). 
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launched and entered Earth’s orbit.7 It was the result of a multi-
disciplinary collaboration between civilian and military scientists, 
consisting of Dr. William H. Pickering and the Jet Propulsion 
Laboratory at the California Institute of Technology, Dr. James Van 
Allen8 of the University of Iowa, and Dr. Wernher von Braun’s United 
States Army Redstone Arsenal team.9 The United States Congress also 
acted swiftly: on July 29, 1958, President Eisenhower signed into law 
the National Aeronautics and Space Act,10 establishing, among other 
things, the National Aeronautics and Space Council,11 and the civilian 
National Aeronautics and Space Administration (“NASA”).12 Its 1958 
budget was $89 million, 0.1 percent of the Federal Budget. But by the 
height of the Space Race in 1966, NASA’s budget totaled nearly $6 
billion, or 4.41 percent of the Federal Budget.13 The Race to master 
Outer Space had begun and, although the United States was behind, it 
was running to win. 
 
7. Explorer-I and Jupiter-C, The First United States Satellite and Space 
Launch Vehicle, NASA, https://history.nasa.gov/sputnik/expinfo.html 
(last visited Feb. 5, 2018). 
8. The same Van Allen for which the subsequently-discovered eponymous 
radiation belts are named; See James A. Van Allen, in ENCYCLOPÆDIA 
BRITANNICA (2018). 
9. Sputnik and The Dawn of the Space Age, supra note 3. 
10. National Aeronautics and Space Act of 1958, Pub. L. No. 85-568, 72 Stat., 
426 (unamended). 
11. Id. at § 201(a)(1)-(6) (comprising of the President, Secretary of State, 
Secretary of Defense, NASA Administrator, the Chairman of the Atomic 
Energy Commission, and not more than one additional government 
appointee). 
12. National Aeronautics and Space Act of 1958 at § 204(a) (showing that 
the 1958 Act also provides for a Civilian-Military Liaison Committee 
comprising a Presidentially-appointed Chairman, one or more 
representatives from the Departments of Defense, Army, Navy, and Air 
Force, as assigned by the Secretary of Defense, and NASA-assigned 
representatives, equal in number to the military members).See also 
Gerhard Peters & John T. Wooley, Dwight D. Eisenhower: Statement by 
the President Upon Signing the National Aeronautics and Space Act of 
1958, THE AMERICAN PRESIDENCY PROJECT, http://www.presid
ency.ucsb.edu/ws/?pid=11146 (noting that the “nucleus” for NASA was 
rooted in the 1915-established National Advisory Committee for 
Aeronautics). 
13. NASA Budgets: US Spending on Space Travel Since 1958 UPDATED, 
THE GUARDIAN, https://www.theguardian.com/news/datablog/20
10/feb/01/nasa-budgets-us-spending-space-travel (last visited Jan. 2, 
2018). Adjusted for inflation in January 2017: $89 million in Jan. 1958 = 
$755.69 million; $5.933 billion in Jan. 1966 = $45.307 billion. See CPI 
Inflation Calculator, available at https://data.bls.gov/cgi-bin/cpicalc.
pl?cost1=5933&year1=196601&year2=201701)). 
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Introduction 
“One test result is worth one thousand expert opinions.” 
-Wernher von Braun14 
 
One of the many fascinating and potentially revolutionary 
developments in the field of biomedical research in recent years has 
been the development of molecular tools that enable scientists to engage 
in Targeted Genomic Editing (“TGE”). TGE empowers scientists to 
efficiently and precisely modify or delete a gene of interest or to add 
new genetic sequences to a target of interest.15 Recently, through the 
combined efforts of many United States and international researchers, 
a system known as CRISPR-Cas9 has emerged as both a relatively 
inexpensive and more precise method of TGE than any previously 
recognized in the field.16 With the discovery of CRISPR-Cas9, the 
potential for TGE-mediated gene therapies has never been greater. It 
is likely that, with time and effort, TGE may revolutionize medicine as 
we know it, giving new hope to both current patients and carriers of 
heritable genetic disorders. TGE could also result in “human 
enhancement.”17 The very idea that we could “exert control over human 
heredity with this technique”18 raises questions as to whether tinkering 
 
14. International Space Hall of Fame, Wernher Von Braun, NEW MEXICO 
MUSEUM OF SPACE HISTORY, http://www.nmspacemuseum.org/hall
offame/detail.php?id=29 (last visited Feb. 5, 2018) (von Braun is thought 
to have said this in 1972; see Duncan Haughey, 10 More Quotes That 
Make You a Better Project Manager, PROJECT SMART (Feb. 23, 2013), 
https://www.projectsmart.co.uk/10-more-quotes-that-make-you-a-better
-project-manager.php. 
15. See Jennifer Walker-Daniels, Genomic Engineering, 3 MATERIALS & 
METHODS (last updated Aug. 2, 2016), available at https://www.lab
ome.com/method/Genomic-Engineering.html#ref29. 
16. See Le Cong, et al., Multiplex Genome Engineering Using CRISPR/Cas 
System, 339 SCIENCE 819, 819 (2013). See also Prashant Mali, et al., RNA-
Guided Human Genome Engineering via Cas9, 339 SCIENCE 823, 823 
(2013). 
17. See David Masci, Human Enhancement: The Scientific and Ethical 
Dimenstions of Striving for Perfection, PEW RES. CTR. INTERNET & TECH. 
(July 26, 2016), http://www.pewinternet.org/essay/human-enhancement-
the-scientific-and-ethical-dimensions-of-striving-for-perfection/; see also 
Human Enhancement, INST. ETHICS & EMERGING TECH., 
https://ieet.org/index.php/tpwiki/human_enhancement (last visited 
Mar. 27, 2018) (defining human enhance-ment as referring to “any 
attempt to temporarily or permanently overcome the current limitations 
of the human body through natural or artificial means”). 
18. See Nathaniel Comfort, Can We Cure Genetic Diseases Without Slipping 
Into Eugenics? THE NATION (July 16, 2015), https://www.thenat
ion.com/article/can-we-cure-genetic-diseases-without-slipping-into 
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with the blueprint of life is even a good idea to begin with. But only 
those who have mastered the technology will know the full breadth of 
its scope. Are we capable of mastering the “Inner Space” of our cells? 
If we can, should we do so? If this nation is not the first to know if we 
can, will we be able to decide whether we should?  
The race to explore and, eventually, master this “Inner Space” has 
already begun. On October 28, 2016, a team of researchers in China 
initiated the first clinical trial to administer cells containing genes 
edited with the “revolutionary CRISPR-Cas9 technique.”19 In response 
to this, Dr. Carl June of the University of Pennsylvania remarked that 
this would “trigger a biomedical ‘Sputnik 2.0’… between China and the 
United States.”20 Clinical researchers in the United States expect to 
begin CRISPR-Cas9 human trials within the next year,21 three years 
behind their Chinese counterparts.22 This lag is owed, in part, to the 
“few[er] regulatory hurdles [in China] to testing it on humans.”23 After 
the tragic death in 1999 of Jesse Gelsinger,24 a profound “chilling effect 
 
eugenics/ (quoting American biologist and 1975 Nobel laureate in 
Physiology or Medicine David Baltimore). 
19. David Cyranoski, CRISPR Gene-Editing Tested in a Person for the First 
Time, NATURE NEWS (Nov. 15, 2016), http://www.nature.com/news/cri
spr-gene-editing-tested-in-a-person-for-the-first-time-1.20988; see also 
China Is Surging Ahead In The Race To Beat Cancer With CRISPR, 
WALL STREET PIT (2017), https://www.wsj.com/articles/china-pushes-
ahead-with-human-gene-trials-1493380057 (reporting Jia Wei at Nanjing 
Clinical Cancer Institute initiated the second such trial on Apr. 28, 2017). 
20. See Cyranoski, supra note 19. 
21. Preetika Ranaet et al., China Unhampered by Rules, Races Ahead in 
Gene-Editing Trials, THE WALL STREET JOURNAL (Jan. 21, 2018), 
https://www.wsj.com/articles/china-unhampered-by-rules-races-ahead-
in-gene-editing-trials-1516562360; see also Emily Mullin, CRISPR in 
2018: Coming to a Human Near You, MIT TECH. REV. (Dec. 18, 2017). 
22. Id. 
23. Id. 
24. Jesse was an 18-year old afflicted with ornithine transcarbamylase 
deficiency (“OTCD”), and was participating in an experimental gene 
therapy trial at the Institute for Human Gene Therapy (“IHGT”) at the 
University of Pennsylvania. See Institute for Human Gene Therapy 
Responds to FDA, ALMANAC BETWEEN ISSUES (Feb. 14, 2000), 
https://almanac.upenn.edu/archive/between/FDAresponse.html. He 
“died from complications of vector administration,” resulting in “substan-
tial reform[]” in regulatory oversight of human subjects research. See 
James M. Wilson, Lessons Learned from the Gene Therapy Trial for 
Ornithine Transcarbamylase Deficiency, 96 MOLECULAR GENETICS & 
METABOLISM 151, 151, 153 (2009). 
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on the field”25 of gene therapy occurred,26 but clinical researchers have 
been gradually returning to the prospect of modifying genes in humans 
to ameliorate disease. For example, on November 13, 2017, California 
clinicians treated Brian Madeux with an infusion of “billions of copies 
of a corrective gene and a genetic tool to cut his DNA in a precise 
spot.”27 Brian suffers from Hunter syndrome, an inherited condition 
resulting from a mutation in a gene28 for an enzyme29 that cells need to 
break down large sugar molecules.30 Because of Hunter syndrome, Brian 
has had to undergo twenty-six operations—approximately one surgery 
for each 1.6 years of life.31 This trial, using a more tried TGE tool in 
Zinc Finger Nucleases (“ZFNs”)32, has given Brian and others renewed 
hope that their disease state may not be one of permanence.33 
 
 
 
 
 
 
 
 
25. JAMES KOZUBEK, MODERN PROMETHEUS: EDITING THE HUMAN GENOME 
WITH CRISPR-CAS9 157 (2016) (quoting Richard C. Mulligan, Ph.D., 
Harvard Stem Cell Institute). 
26. Indeed, there has even been a chilling effect in the language used to refer 
to such studies, as some scientists and bioethicists prefer the term “gene 
transfer” as more accurate than of “gene therapy,” as “therapy” implies 
effective/efficacious treatment that is out of the experimental stages. See, 
e.g., Ranaet et al., supra note 21. 
27. Marilynn Marchione, AP Exclusive: US Scientists Try 1st Gene Editing 
in the Body, ASSOCIATED PRESS (Nov. 15, 2017), https://www.apnews
.com/4ae98919b52e43d8a8960e0e260feb0a/AP-Exclusive:-US-scientists-
try-1st-gene-editing-in-the-body; see also Jocelyn Kaiser, A Human has 
been Injected with Gene-Editing Tools to Cure His Disabling Disease. 
Here’s What You Need to Know, SCIENCE (2017), http://www.sciencemag
.org/news/2017/11/human-has-been-injected-gene-editing-tools-cure-his-
disabling-disease-here-s-what-you. 
28. See Genetics Home Reference, Mucopolysaccharidosis Type II, U.S. NAT’L 
LIBR. MED., NIH, https://ghr.nlm.nih.gov/condition/mucopolysaccharid
osis-type-ii#genes (last visited Feb. 5, 2018). 
29. See id. 
30. Id. 
31. Marchione, supra note 27. 
32. See Walker-Daniels, supra note 15. 
33. Id. Said Madeux after the procedure: “I’m nervous and excited, I’ve been 
waiting for this my whole life, something that can potentially cure me.” 
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TGE, as a molecular tool, may be employed in a variety of 
organisms, including humans. Two routes of directing therapies exist 
for TGE: one, in gene transfers aimed to treat patients living with 
myriad genetic disorders, or two, to modify the human germline: that 
is, the sex cells (sperm and egg) which form an embryo during the 
process of fertilization.34 In bridging the gap between the laboratory 
bench and the patient’s bedside, researchers must be empowered to 
study closely the utility of TGE in a human context, including on 
human embryos. Unfortunately, current federal law and regulation of 
federal funding of scientific research precludes TGE utilizing human 
embryos, an effective barrier to innovation.35 The Dickey-Wicker 
Amendment, incorporated into annual Congressional appropriations 
bills since 1996, prohibits appropriated funding from being used to 
conduct research in which human embryos are destroyed.36 The 
National Institutes of Health (“NIH”) distributes federal funding of 
biomedical research with more than 80 percent of its $32.3 billion 
annual budget going to research universities and institutions.37 NIH 
Guidelines presently comply with established law, noting that the 
agency “ . . . will not at present entertain proposals for germ line 
alteration.”38 By contrast, at least three international governments—
 
34. See generally R.C. Wykes & G. Lignani, Gene Therapy and Editing: Novel 
Potential Treatments for Neuronal Channelopathies, 132 
NEUROPHARMACOLOGY 108 (2018). 
35. This is not to say there exist no options for scientists to secure funding 
for these kinds of projects. Private funds may be available, as well as in 
several states, where State Initiatives have been authorized over the years 
to fund stem cell and other embryonic research. See generally CONG. RES. 
SERV., DOMESTIC SOC. POL’Y DIVISION, Stem Cell Research: State 
Initiatives (May 19, 2006). The California Stem Cell Initiative, under the 
California Institute for Regenerative Medicine (“CIRM”) is one such 
example of a State Initiative (see, e.g., Joel W. Adelson & Joanna K. 
Weinberg, The California Stem Cell Initiative: Persuasion, Politics, and 
Public Science, 100 AM. J. PUB. HEALTH 446, 446 (2010)). 
36. Embryos, Pub. L. No. 104-99, § 128, 110 Stat. 34 (1996). 
37. Or, put differently, more than $25.84 billion per annum. See What We 
Do: Budget, NIH, (2017), https://www.nih.gov/about-nih/what-we-
do/budget (last visited Jan. 30, 2018). 
38. Francis S. Collins, Director, NIH, Statement on NIH Funding of Research 
Using Gene-Editing Technologies in Human Embryos, NAT’L INST. OF 
HEALTH (Apr. 28, 2015), https://www.nih.gov/about-nih/who-we-are/ni
h-director/statements/statement-nih-funding-research-using-gene-editing
-technologies-human-embryos [hereinafter Collins Statement]. 
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the People’s Republic of China,39 the United Kingdom,40 and Sweden41—
have tentatively embraced the idea by funding research projects that 
include CRISPR-Cas9 experimentation on human embryos, and at the 
same time pushing the United States even further behind in this ‘Inner 
Space Race.’ 
If we consider ourselves to be—and if we are intent on remaining—
the preeminent intellectual superpower of the world, we must embrace 
a national policy that, at least, opens the door to contemplating 
federally-funded embryonic research with respect to TGE, and 
accelerates research and development in this area. It is in both the 
national interest—and the public interest—to allocate the requisite 
resources to develop this technology and its likely successors. If we fail 
to do so, we risk: (1) falling behind more ambitious nations who seek 
to know, as an unambiguous matter of government policy, the metes 
and bounds of TGE; (2) being dictated to by those nations about what 
should and should not be done once the technology has been mastered; 
and (3) prospectively forfeiting subsequent intellectual property rights, 
including the right to exclude, likely to result from the fruits of the 
scientific exercise.42 Our national interest demands that such reasonable 
action be taken as to both enable and empower our scientific 
community to more effectively chart this potential “final frontier” of 
Inner Space. 
This Note advocates for the federal government funding of TGE 
experimentation on human embryos, and recommends additional 
funding to accelerate scientific development and inquiry. It also recon-
siders the question of prohibiting the federal funding of embryonic 
experimentation in a controlled research environment, while suggesting 
ways of overcoming the short- and medium-term ethical questions 
certain to arise. Part I will provide a brief scientific and historical 
 
39. See David Cyranoski & Sara Reardon, Embryo Editing Sparks Epic 
Debate, NATURE NEWS (Apr. 29, 2015), http://www.nature.com/news
/embryo-editing-sparks-epic-debate-1.17421#/b1. 
40. See Ewen Callaway, UK Scientists Gain Licence to Edit Genes in Human 
Embryos, NATURE NEWS (Feb. 1, 2016), https://www.nature.com
/news/uk-scientists-gain-licence-to-edit-genes-in-human-embryos-
1.19270. 
41. See Interview with Fredrik Lanner Who is CRISPR’ing Healthy Human 
Embryos, THE NICHE: KNOEPFLER LAB STEM CELL BLOG, (Sep. 26, 2016), 
available at https://ipscell.com/2016/09/interview-with-fredrik-lanner-
who-is-crispring-healthy-human-embryos/ [hereinafter Lanner Interview]. 
42. Of the total 589,410 total US Utility Patent filings in 2015, 301,075 or 
more than 51% were filed by inventors outside of the United States. 
Number of Utility Patent Applications Filed in the United States, By 
Country of Origin, Calendar Years 1965 to Present, U. S. PATENT & 
TRADEMARK OFFICE, (2018), https://www.uspto.gov/web/
offices/ac/ido/oeip/taf/appl_yr.htm. 
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background of TGE, emphasizing CRISPR-Cas9. Part II will discuss 
recent and ongoing developments at home and abroad and demonstrate 
the risk of an emerging knowledge gap in this field. Part III will discuss 
where the debate stands in this country, and examine the barriers to 
research in this field. Finally, Part IV will outline a number of 
recommendations in view of Part III, and how we might overcome 
legitimate concerns about what kinds of research are in the public and 
national interest. 
I. On Targeted Genome Editing: Towards Mastering 
(and Possibly Redesigning) the Blueprint of Life; a 
“Brief” History of CRISPR-Cas9 Development 
“I have learned to use the word ‘impossible’ with the greatest 
caution.” 
-Wernher von Braun43 
 
TGE, also referred to as genome engineering, was first recognized 
by Nature Methods as “Method of the Year” in 2011.44 The genome 
refers to an organism’s entire deoxyribonucleic acid (“DNA”) sequence, 
which is arranged by a double helical base that pairs between two of 
four nucleotide bases: adenine (A), thymine (T), cytosine (C), and 
guanine (G). Approximately three billion base pairs make up the human 
genome and are arranged into twenty-three pairs of chromosomes 
contained within the nucleus of all human cells. Within these 
chromosomes, DNA sequences form functional units known as genes 
that provide the blueprints for proteins to carry out cellular functions.45 
 
43. Quoted by Michael Yarus, in Life From an RNA World: The Ancestor 
Within (2010). 
44. Nature Publishing Group, Method of the Year 2011, 9 NATURE METHODS 
1, 1 (2012), available at http://www.nature.com/nmeth/journal/v9/n
1/full/nmeth.1852.html [hereinafter Method 2011]. Nature Methods is 
noted by the NIH as a “high-impact journal,” a highly influential journal 
in the field of medical and biological research. The Nature family of 
journals includes 11 of the top 20 high-impact journals according to the 
NIH. See High Impact Journals, NAT’L INST. ENVTL. HEALTH SCI., 
https://tools.niehs.nih.gov/srp/publications/highimpactjournals.cfm 
(last visited Mar. 5, 2018). 
45. “Francis Crick’s ‘central dogma’ of molecular biology, put simply, is 
[ . . . ] ‘DNA makes RNA, RNA makes proteins, proteins make us.’” See 
Sarah A. Leavitt, Deciphering the Genetic Code: Marshall Nirenberg, 
OFFICE OF NIH HISTORY (2010), https://history.nih.gov/exhibits
/nirenberg/glossary.htm. See also Francis Crick, On Protein Synthesis, in 
SYMPOSIA OF THE SOCIETY FOR EXPERIMENTAL BIOLOGY, NUMBER XII: 
THE BIOLOGICAL REPLICATION OF MACROMOLECULES, 138-63 (1958). 
Although the actual science of molecular biology has been found to be far 
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The genome is simultaneously the blueprint for and the manufactory of 
life. Like any good factory, the genome has undergone renovations 
throughout evolutionary time. TGE has the potential to technologically 
accelerate such renovations. 
Essentially, TGE enables scientists to “introduce targeted, tailored 
changes into the genomes of several species.”46 Considered a “reverse 
genetics” approach, TGE effectively enables scientists to synthetically 
engineer particular gene sequences of interest.47 The researcher may 
then analyze the subsequent phenotypic48 consequences of that 
engineering. Reverse genetics is contrasted with the classical, “forward 
genetics” approach, where scientists begin by observing a mutant 
phenol-type in an organism, and then identifying the relevant 
mutation.49 Reverse genetics afford greater flexibility and precision to 
researchers, because with reverse genetics, she can create the cause50 
and analyze the effect, rather than observe an effect and study the 
cause.51 
Until recently, the three major methods for TGE were DNA binding 
protein-based transcription activator-like effector nucleases (“TALENs”),52 
ZFNs,53 and meganucleases (“MGNs”).54 The CRISPR/ Cas-9 system is 
the “new kid on the block” in the realm of TGE, though it has been 
 
more complex than the central dogma articulated by Crick in 1958, the 
essential principle remains substantially true. 
46. Method 2011, supra note 44. 
47. Reverse Genetics, in AN INTRODUCTION TO GENETIC ANALYSIS (7th ed. 
2000), available at https://www.ncbi.nlm.nih.gov/books/NBK21843/. 
48. “Phenotypic” means of or relating to phenotypes, or the observable 
features of or differences between organisms. Often contrasted with geno-
typic. Phenotypic, OXFORD ENGLISH DICTIONARY (3rd Ed., 2005), 
http://www.oed.com/view/Entry/262706?redirectedFrom=phenotypic#
eid. 
49. Reverse Genetics, supra note 47. 
50. By introducing a mutation in a gene or DNA sequence of interest. See id. 
51. Id. 
52. See Jean-Paul Iyombe-Engembe & Jacques P. Tremblay, The Advances 
and Challenges of Gene Therapy for Duchenne Muscular Dystrophy, 1 J. 
GENETICS MED. GENE THERAPY 19, 20 (2017). 
53. Id. 
54. Id. 
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studied around the world and as far back as 1993.55 Francisco Mojica56 
and colleagues studied the Clustered Regularly Interspaced Short 
Palindromic Repeats (“CRISPR”) for a number of years.57 They 
predicted that CRISPR sequences function as a sort of prokaryotic58 
immune system59, utilized to fend off infection by foreign organisms. In 
2005, Alexander Bolotin and colleagues found that an interesting 
 
55. In 1993, Francisco Mojica and colleagues at the University of Alicante, 
Spain, came upon a previously unobserved DNA fragment while studying 
the halophilic (meaning grows in or tolerates saline conditions; halophilous. 
See Halophilic, OXFORD ENGLISH DICTIONARY (1976), available at 
http://www.oed.com/view/Entry/83636?redirectedFrom=h
alophilic#eid.Archaeal microbe Haloferax mediterranei. See Francisco 
Mojica, Transcription at Different Salinities of Haloferax mediterranei 
Sequences Adjacent to Partially Modified PstI Sites, MOLECULAR 
MICROBIOLOGY 613 (1993) [hereinafter Mojica 1993]. This fragment 
comprised “multiple copies of a near-perfect, roughly palindromic, 
repeated sequence of 30 bases, separated by spacers of roughly 36 bases—
that did not resemble any family of repeats known in microbes.” See Eric 
S. Lander, The Heroes of CRISPR. 164 CELL 18, 21-22 (2016). See also 
CRISPR Timeline, THE BROAD INST.,  
https://www.broadinstitute.org/what-broad/areas-focus/project-
spotlight/crispr-timeline (last visited Jan 23, 2017) [hereinafter CRISPR 
Timeline] (The above history is not exhaustive: the Broad Institute’s 
CRISPR Timeline provides additional highlights regarding the discovery 
of CRISPR not covered in this Note, including work by Koonin et al. at 
the NIH, Hovarth et al. at Danisco France SAS, van der Oost at the 
University of Wageningen, Netherlands, and the work of Marraffini & 
Sontheimer at Northwestern University, Chicago, IL). 
56. Mojica 1993, supra note 55. 
57. See Francisco Mojica, Intervening Sequences of Regularly Spaced 
Prokaryotic Repeats Derive from Foreign Genetic Elements. J. OF 
MOLECULAR EVOLUTION 174, 174 (2005). In 2005, Mojica reported that 
CRISPR in Haloferax mediterranei shared identity with sequences from 
the bacteriophage (a virus that infects and replicates inside of a 
bacterium) genome. See also C. Pourcel et al., CRISPR Elements in 
Yersinia Pestis Acquire New Repeats by Preferential Uptake of 
Bacteriophage DNA, and Provide Additional Tools for Evolutionary 
Studies, 151 MICROBIOLOGY 653 (2005). 
58. “Prokaryote” means a single-cell prokaryotic organism, contrasted with 
eukaryote. Prokaryotes are often classified by phylogenetic kingdom, as 
either Archaea or Bacteria. Prokaryote, OXFORD ENGLISH DICTIONARY 
(3rd Ed., 2007), available at http://www.oed.com/view/Ent
ry/152285?redirectedFrom=prokaryote#eid. 
59. In 2007, Rodolphe Barrangou and colleagues affirmatively demonstrated 
that the CRISPR locus comprised a bacterial adaptive immune system, 
where the bacteria can resist infection by bacteriophages. See Rodolphe 
Barrangou, CRISPR Provides Acquired Resistance Against Viruses in 
Prokaryotes, 315 SCIENCE 1709, 1709 (2007) (the bacterium can resist 
infection because it incorporates a part of the invading virus genome into 
its CRISPR locus). 
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CRISPR locus60 in the bacterium Streptococcus thermophilus contained 
what they termed CRISPR-associated (“Cas”) genes.61 One of them, 
Cas9, was predicted to have nuclease62 activity,63 or the ability to ‘cut’ 
a DNA sequence. In 2007, Randolphe Barrangou and his team at 
Danisco64 in Madison, Wisconsin, showed that bacteria containing both 
CRISPR and Cas9 can inactivate and defeat infection by bacteriophage.65 
In 2010, Sylvain Moineau and colleagues at the University of Leval, 
Quebec, reported that the combination of CRISPR and Cas9 (and only 
 
60. “Locus” means the place in which something is situated or occurs. In later 
use also: the effective or perceived location of something abstract. Locus, 
OXFORD ENGLISH DICTIONARY (3rd Ed., 2015), available at 
http://www.oed.com/view/Entry/109673?rskey=HjtkEH&result=1#eid 
(here, locus refers to the location in the S. thermophilus genome where 
CRISPR was found). 
61. Bolotin also demonstrated the need for spacers, called protospacer 
adjacent motifs (PAMs) were necessary for target recognition. Alexander 
Bolotin, Clustered Regularly Interspaced Short Palindrome Repeats 
(CRISPRs) Have Spacers of Extrachromosomal Origin, 151 MICROBIOLOGY 
2551 (2005). 
62. “Nuclease” means an enzyme that catalyzes the hydrolysis of a phospho-
diester bond of a nucleic acid, cleaving the nucleic acid into smaller units. 
Nuclease, OXFORD ENGLISH DICTIONARY (3rd Ed., 2003), available at 
http://www.oed.com/view/Entry/128933?redirectedFrom=n
uclease#eid. 
63. CRISPR Timeline, supra note 55. See also Bolotin, supra note 61. 
64.  Danisco is a subsidiary of DuPont. See Dupont Major Subsidisaries, DU 
PONT, http://www.dupont.com/subsidiaries.html (last visited Apr. 5, 
2018). Du Pont itself a subsidiary of DowDuPont, Inc. as of September 1, 
2017. See Press Release, Dow Du Pont, DowDuPont™ Merger Successfully 
Completed (Sept. 1, 2017), http://www.dow-dupont.com/news-and-
media/press-release-details/2017/DowDuPont-Merger-Successfully-
Completed/default.aspx. 
65. See Barrangou, supra note 59, at 1711. By 2009, several groups had 
reported the discovery of crRNAs, an abbreviated term for CRISPR-
RNAs. See Stan J. J. Brouns, et al. Small CRISPR RNAs Guide Antiviral 
Defense in Prokaryotes 321 SCIENCE 960, 960-61 (2008). See also Luciano 
A. Marraffini & Erik J. Sontheimer, CRISPR Interference Limits 
Horizontal Gene Transfer in Staphylococci by Targeting DNA, 
322 SCIENCE 1843, 1843 (2008); Caryn R. Hale, et al., RNA-guided RNA 
Cleavage by a CRISPR RNA-Cas protein complex. 139 CELL 945 (2009); 
Caryn Hale, et al. Prokaryotic Silencing (psi)RNAs in Pyrococcus 
Furiosus. RNA 2572 (2008); Reidun K. Lillestol RK, et al. CRISPR 
Families of the Crenarchaeal Genus Sulfolobus: Bidirectional 
Transcription and Dynamic Properties, MOLECULAR MICROBIOLOGY 259 
(2009). crRNAs are short sequences of RNA generated by the CRISPR 
locus and were found to target the invading bacteriophage DNA, and form 
a molecular complex with Cas9. The invading DNA sequence is 
subsequently cleaved (cut) and thus inactivated. See Barrangou, supra 
note 59, at 1711. 
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Cas9) could effectively promote precise DNA breaks.66 Cas9 may thus 
be thought of a molecular ‘scissors,’ able to cut a target DNA precisely 
and accurately.67 
A few more pieces were needed to complete the molecular puzzle of 
the CRISPR-Cas9 system. In 2011, Emmanuelle Charpentier’s group at 
the University of Umeå, Sweden, discovered that tracrRNA68 could 
direct Cas9 to a particular locus.69 Cas9’s molecular mechanism was 
further elucidated in 2012, when Virginijus Siksnys et al. at Vilnius 
University in Lithuania “showed that they could reprogram Cas9 to 
target a site of their choosing by changing the sequence of the crRNA.70 
These findings were confirmed and extended by Charpentier in 
international collaboration with Jennifer Doudna’s lab at UC-Berkeley 
that same year. 71 The potential use for an otherwise intriguing bacterial 
immune system demonstrated the “ . . . potential to exploit the system  
 
 
 
for RNA-programmable genomic editing.”72 This means CRISPR-Cas9 
may represent an affordable and precise system by which scientists— 
66. CRISPR Timeline, supra note 55. See also J Garneau, The CRISPR/Cas 
Bacterial Immune System Cleaves Bacteriophage and Plasmid DNA, 468 
NATURE 67 (2010). 
67. Elizabeth Pennisi, Popular Gene-Editing Technique Gets Sharper 
Molecular Scissors, SCIENCE NEWS (Sep. 25, 2015), http://ww
w.sciencemag.org/news/2015/09/popular-gene-editing-technique-gets-
sharper-molecular-scissors. 
68. “TracrRNA” means “trans-activating crRNA with 24 nucleotide 
complementarity to the repeat regions of crRNA precursor transcripts.” 
“crRNA” is a short RNA that “silence[s] foreign nucleic acids in a 
sequence-specific manner . . . the maturation of [which] represents a key 
event in CRISPR activation.” Elitza Deltcheva et al., CRISPR RNA 
Maturation by Trans-Encoded Small RNA and Host Factor RNase III, 
431 NATURE 602, 602 (2011). 
69. Id. at 604. 
70. CRISPR Timeline, supra note 55 [emphasis added]. The Charpentier-
Doudna collaboration showed that crRNAs base-paired with tracrRNA, 
combining to form a structure that could direct Cas9 to cleave a target 
DNA. They further showed that a molecularly-engineered chimera 
tracrRNA:crRNA (also called single guide RNA, or sgRNA) has 
comparative function to the naturally-observed two-RNA structure. See 
Giedrius Gasiunas et al., Cas9-crRNA Ribonucleoprotein Complex 
Mediates Specific DNA Cleavage for Adaptive Immunity in Bacteria, 109 
PROC. NAT’L ACAD. SCI. E2579, E2579 (2012). 
71. See Martin Jinek et al., A Programmable Dual-RNA-guided DNA 
Endonuclease in Adaptive Bacterial Immunity, 337 SCIENCE 816, 816-21 
(2012). 
72. Id. at 816. 
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and eventually clinicians—might actually have the capability of 
engineering the genome itself, curing disease through somatic73 gene 
therapy or even enhancing human characteristics through sequence 
additions or deletions. 
The role for the CRISPR-Cas9 system as a tool for TGE was finally 
revealed in 2013, when Feng Zhang’s (Broad Institute of MIT and 
Harvard) and George Church’s (Harvard Medical School, Department 
of Genetics) groups, published back-to-back articles in Science 
reporting successful editing of cell genomes using CRISPR-Cas9 in 
eukaryotic74 cells.75 Since then, CRISPR-Cas9 has burst on to the 
publication scene, with scientists all over the world using CRISPR to 
perform TGE in myriad eukaryotic organisms, from Drosophila 
melanogaster (fruit fly)76 to Danio rerio (zebrafish).77 In 2015, Science  
declared CRISPR/Cas9 the “Breakthrough of the Year.”78 As 2006  
 
 
 
 
 
 
 
73. “Somatic” means of or relating to the (or a) body; bodily corporeal, 
physical [ . . . ] [r]elating to the soma in contrast to the germ. Somatic, 
OXFORD ENGLISH DICTIONARY, available at 
http://www.oed.com/view/Entry/184422?redirectedFrom=somatic#eid 
(last visited Mar. 8, 2018). 
74. Specifically, human and mouse cells. See Lander, supra note 55, at 25. 
75. See Cong et al., supra note 16, at 822. See also Mali et al., supra note 16, 
at 823. 
76. See, e.g., Andrew R. Bassett and Ji-Long Hu, CRISPR/Cas9 Genome 
Editing in Drosophila, 41 J. GENETICS & GENOMICS 7 (2014) (One of 162 
articles published since 2013 using the following Boolean search in 
PubMed: “CRISPR AND Cas9 AND Drosophila”) (last queried Apr. 8, 
2018). 
77. See, e.g., Thomas O. Auer & Filippo Del Bene, CRISPR/Cas9 and 
TALEN-Mediated Knock-in Approaches in Zebrafish, 69 METHODS 
(2013), 142-50. (One of 260 articles published since 2013 using the 
following Boolean search in PubMed: “CRISPR AND Cas9 AND 
zebrafish) (last queried Apr. 8, 2018). 
78. Science News Staff, And Science’s 2015 Breakthrough of the Year is . . . , 
SCIENCE (Dec. 17, 2015), http://www.sciencemag.org/news/2015/12/and-
science-s-breakthrough-year. 
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Nobel Prize winner79 for Physiology or Medicine Craig Mello80 noted 
in 2014, “[CRISPR/Cas9] is really powerful, [ . . . ] because now you 
can essentially change a genome at will to almost anything you want. 
The sky’s the limit.”81 
Why is the CRISPR-Cas 9 system such a useful molecular tool? 
First, it is a system that is relatively simple and inexpensive compared 
to other known methods as it is comprised of only a few molecular 
components.82 Particularly, its components include the CRISPR locus 
and associated crRNA, the Cas9 protein, and a tracrRNA. Due to the 
RNA-based nature of CRISPR-Cas9 system, the RNA molecules that 
direct the system to the gene of interest are much easier and less 
expensive to synthesize than the other existing technologies mentioned 
above.83 Second, CRISPR-Cas9 is more accurate, and thus more 
effective at generating a desired mutation84 than other protocols.85 
 
79. The Nobel Prize in Physiology or Medicine 2006, NOBELPRIZE.ORG, 
https://www.nobelprize.org/nobel_prizes/medicine/laureates/2006/ 
(last visited Feb. 5, 2018). 
80. Along with Andrew Fire, Mello was one of the discoverers of the RNA 
interference (or RNAi) system. 
81. Joe Palca, A CRISPR Way to Fix Faulty Genes, NPR, ALL THINGS 
CONSIDERED (June 26, 2014), http://www.npr.org/sections/health-sho
ts/2014/06/26/325213397/a-crispr-way-to-fix-faulty-genes. 
82. Robert Sanders, Simple Technology Makes CRISPR Gene Editing 
Cheaper, BERKELEY NEWS (July 23, 2015), http://news.berkeley.edu
/2015/07/23/simple-technology-makes-crispr-gene-editing-cheaper/. 
83. See Walker-Daniels supra note 15; F. Ann Ran, et al., Genome 
Engineering Using the CRISPR-Cas9 System, 8 NATURE PROTOCOLS 
2281, 2281(2013). 
84. See Woong Y. Hwang, et al., Heritable and Precise Zebrafish Genome 
Editing Using a CRISPR-Cas System, 8 PLOS ONE (2013), e68708, 1-9. 
See also Zhengyan Feng et al., Efficient Genome Editing in Plants Using 
a CRISPR/Cas System, 23 CELL RES. 1229, 1229 (2013). 
85. See Jeffrey C. Miller, et al., A TALE Nuclease Architecture for Efficient 
Genome Editing, 29 NATUREBIOTECHNOLOGY 143, 143(2011). See also 
Claudio Mussolino, et al., A Novel TALE Nuclease Scaffold Enables High 
Genome Editing Activity in Combination with Low Toxicity, 39 NUCLEIC 
ACIDS RES. 9283, 9281 (2011). See also Morgan L. Maeder, et al., Rapid 
“Open-Source” Engineering of Customized Zinc-Finger Nucleases for 
Highly Efficient Gene Modification, 31 MOLECULAR CELL 294, 296 (2008). 
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Finally, the cleavage activity of the CRISPR-Cas9 system is remarkably 
precise;86 a key element of a robust TGE system.87 
Perhaps most importantly, researchers have quickly recognized the 
potential therapeutic use for this technology in treating both inherited 
and de novo (arising spontaneously) human disease caused by genetic 
mutation.88 These works represent “[t]he pinnacle of four decades of 
research” as CRISPR will potentially take biomedical research to new, 
unprecedented levels and more effectively study genetic mechanisms of 
pathology with a “hitherto unimaginable level of model fidelity.”89 A 
well-deserved “Breakthrough of the Year,” to be sure! Researchers could 
use TGE as a therapy by modifying the genome of a human embryo to 
add, remove, or replace gene sequences to abrogate genetic mutations. 
Presuming such a modified embryo could be successfully brought to 
term90 and implanted successfully in humans, TGE might lead to the 
 
86. See Cong, et al., supra note 16, at 819 (Zhang’s group “engineered two 
different type II CRISPR/Cas systems and demonstrate that Cas9 
nucleases can be directed by short RNAs to induce precise cleavage at 
endogenous genomic loci in human and mouse cells.”).  
       However, there are at least two concerns raised in recent studies to bring 
CRISPR-Ca9 into a clinical setting. The first a concern over CRISPR-
Cas9 utilization causing “off-target mutations,” a problem that scientists 
are working towards resolving. See, e.g., Yanfang Fu, et al., High 
Frequency Off-Target Mutagenesis Induced by CRISPR-Cas Nucleases in 
Human Cells, 31 NATURE BIOTECHNOLOGY 822 (2013). See also Adrian 
Veres, et al., Low Incidence of Off-Target Mutations in Individual 
CRISPR-Cas9 and TALEN Targeted Human Stem Cell Clones Detected 
by Whole-Genome Sequencing, 15 CELL STEM CELL 27 (2014); Daesik Kim, 
et al., Digenome-seq: Genome-Wide Profiling of CRISPR-Cas9 Off-
Target Effects in Human Cells, 12 NATURE METHODS (2015), 237, 237-43.  
       The second, and more recent, issue was raised by Matthew Porteus’ group 
at Stanford, demonstrating an adaptive immune response to Cas9 in 
humans. See Carsten T. Charlesworth et al., Identification of Pre-Existing 
Adaptive Immunity to Cas9 Proteins in Humans, BIORXIV (Jan. 5, 2018), 
https://www.biorxiv.org/content/early/2018/01/05/243345.full.pdf+ht
ml; Andrew Joseph, CRISPR Hits a Snag: Our Immune Systems May 
Attack the Treatment, STAT (Jan. 8, 2018), https://www.statnews.com/
2018/01/08/immunity-crispr-cas9/. 
87. See Alex Reis, CRISPR/Cas9 and Targeted Genome Editing: A New Era 
in Molecular Biology. NEB® EXPRESSIONS, NEW ENG. BIOLABS 3 (2014). 
88. Mark A. DeWitt, et al., Selection-Free Genome Editing of the Sickle 
Mutation in Human Adult Hematopoietic Stem/Progenitor Cells, 360 SCI. 
TRANSLATIONAL MED. 1, 1 (2016). 
89. Simon N. Waddington, et al., A Broad Overview and Review of CRISPR-
Cas Technology and Stem Cells, 2 CURRENT STEM CELL REP. 9, 9 (2016). 
90. This is a separate issue outside of the scope of this Note, but highlights 
the eventual path that this line of research would likely take. 
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eradication of certain diseases.91 Others note that TGE might facilitate 
the enhancement or alteration of human traits.92 And while there are 
no guarantees that the CRISPR-Cas9 system will be the “silver bullet” 
that revolutionizes medicine or makes genetic disorders a thing of the 
past, CRISPR-Cas9 represents an unmistakably significant step forward 
in the field by increasing molecular precision while substantially 
decreasing cost.93 
II. The CRISPR-Cas9 Gold Rush: Developments at 
Home and Abroad 
“With innovation, there isn’t a last nugget. Every new thing 
creates two new questions and two new opportunities.” 
-Jeff Bezos94 
 
Researchers in the United States and around the world have seized 
upon CRISPR-Cas9 to facilitate scientific inquiry. In 2016, for example, 
a collaborative group of researchers from UC-Berkeley and the 
University of Utah’s School of Medicine published their work on 
transplanting CRISPR-Cas9-engineered human hematopoietic stem/ 
progenitor cells correcting the Beta-globulin (“HBB”) gene into 
immunocompromised mice modeling Sickle cell disease (SCD).95 
Notably, this work demonstrated that gene edits to HBB were 
maintained throughout the course of the experiment, likely implying a 
clinical benefit that could translate into humans. And professional  
91. The “low-hanging fruit” of such a therapy would likely begin with single-
gene disorders, such as Huntington disease or Fragile X Syndrome. See, 
e.g., Diseases Treated by Gene Therapy, GENETHERAPYNET.COM, 
http://www.genetherapynet.com/JoomlaTest2/index.php?option=com_
content&view=article&id=164:diseases-treated-with-gene-therapy-&cati
d=97:patient-information&Itemid=14 (last visited Feb. 5, 2018). 
92. See, e.g., Comfort, supra note 18. 
93. Indeed, the lower cost has made rudimentary access to CRISPR systems 
feasible even for do-it-yourselfers. For example, former NASA researcher 
Josiah Zayner, CEO of The ODIN, sells “DIY Bacterial Gene Engineering 
CRISPR Kit[s]” and “Bacterial CRISPR and fluorescent Home Lab 
Kit[s]” for $159 and $209, respectively. See THE ODIN, http://www.the-
odin.com/( last visited Apr. 5, 2018); see also Harry Pettit, Former NASA 
Scientist Wants to Create a New Breed of SUPERHUMANS by ‘Helping 
People Genetically Modify Themselves’ Using DNA Injections (And He’s 
Even Tried Them on Himself), DAILY MAIL (Dec. 29, 2017), 
http://www.dailymail.co.uk/sciencetech/article-5217545/Bohacker-says-
wants-help-humans-modify-genes.html. 
94. Jeff Bezos is the founder of Amazon.com. See The Electricity Metaphor 
for the Web’s Future, TED at 15:17 (Feb. 2003), https://www.ted.com/t
alks/jeff_bezos_on_the_next_web_innovation/transcript. 
95. DeWitt et al., supra note 88. 
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societies, such as the American Society of Human Genetics (“ASHG”) 
have begun to cautiously embrace in vitro germline editing of embryos 
and gametes, though it stops short of approving experiments that would 
“culminate[] in human pregnancy.”96 
Several international groups97 have also experimented with the 
CRISPR/Cas9 editing system in both nonviable98 and viable human 
embryos.99 Time and efforts will tell, but the implications that precise 
TGE could have on human disease are potentially limitless: by 
removing mutations or inserting functional sequences into the genome, 
genetic-related diseases could be mitigated, or human qualities enhanced. 
However, the United States does not currently provide federal funding 
for TGE research on human embryos.100 Why does this matter? While 
animal models are incredibly useful research tools, when it comes to 
direct human benefit, they might not demonstrate an equivalent 
response in human—there is no substitute for the real thing.101 Researchers 
have already begun to incorporate CRISPR/Cas9 into viral vectors for  
96. See Kelly Ormond et al., Human Germline Genome Editing, 101 AM. J. 
OF HUM. GENETICS 167, 171 (2017). 
97. See Cyranoski & Reardon, supra note 39; see also Callaway, supra note 
40; see also Ewen Callaway, Second Chinese Team Reports Gene Editing 
in Human Embryos, NATURE NEWS (Apr. 8, 2016), http://www.nature.
com/news/second-chinese-team-reports-gene-editing-in-human-embryos-
1.19718#/b1 (last visited Mar. 17, 2017) [hereinafter Callaway, Second 
Chinese Team]; Lanner Interview, supra note 41. 
98. “Nonviable” means incapable of surviving; specifically (of a fetus) not 
capable of independent existence. OXFORD ENGLISH DICTIONARY (3rd Ed. 
2003), http://www.oed.com/view/Entry/128160?redirectedFrom=nonvia
ble#eid (last visited: Mar. 17, 2017). 
99. Viable embryos are capable of implanting in the uterine wall and devel-
oping into full-grown humans. See, e.g., Cyranoski & Reardon, supra note 
39. 
100. Steven Latham, Proceed with Caution, U.S. NEWS & WORLD REP. (Feb. 
8, 2016), http://www.usnews.com/opinion/blogs/policy-
dose/articles/2016-02-08/nih-wont-fund-human-embryo-gene-editing-
but-others-will (last visited Mar. 17, 2017). 
101. The National Academies of Science, Engineering and Medicine’s 2017 
Consensus Report, Human Genome Editing: Science, Ethics, and 
Governance lays out a number of valid justifications for research on 
human embryos generally, including “[(1)] Studies of fertilization in vitro[; 
(2) i]mproved culture of early human embryos[ (3) d]evelopment of 
extraembryonic tissues (yolk sac and placenta)[; (4) i]solation an in vitro 
differentiation of pluripotent stem cells[; and (5) i]nvestigations of sperm 
and oocyte development[.]” Human Genome Editing: Science, Ethics and 
Governance, 78 COMM. ON HUM. GENE EDITING: SCI., MED., & ETHICAL 
CONSIDERATIONS, THE NAT’L ACAD. OF SCI., ENGINEERING, & MED., at 78 
(The Nat’l Acad. Press 2017) [hereinafter 2017 Consensus Report]; see 
also Niall Shanks, et al., Are Animal Models Predictive for Humans?, 4 
PHIL. ETHICS & HUMAN. MED. 1, 1(2009). 
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use in conventional somatic gene therapy.102 These successes should give 
patients with genetic diseases hope for the future, but what of the 
generations to come? Genes are passed on from one generation to the 
next through the germline. Genetic disease can either be inherited from 
a mutation in one or both parents, or may arise through random 
mutation.103 At least three nations: (A) the People’s Republic of China; 
(B) the United Kingdom; and (C) the Kingdom of Sweden have 
implemented various national policies embracing governmentally-
sanctioned (and funded) TGE—including CRISPR-Cas9—in the context 
of human embryos. 
A. The People’s Republic of China 
China has published several papers reporting successful TGE on 
human embryos. The first was published April 18, 2015.104 For the first 
time, “scientists reported editing the genomes of human embryos.”105 
Junjiu Huang and colleagues “used tripronuclear (3PN) zygotes to 
further investigate CRISPR/Cas9-mediated gene editing in human 
cells . . . [and] found that CRISPR/Cas9 could effectively cleave the 
endogenous -globin gene (HBB).”106 The embryos used by Huang were 
nonviable and were obtained from local fertility clinics107 with donor 
consent.108 Due to their being nonviable, tripronuclear zygotes would be 
discarded as part of an IVF treatment. Such embryos109 thus make for 
a useful alternative to viable embryos with respect to TGE research.110 
 
102. See, e.g. Ignazio Maggio, et al., Adenoviral Vector Delivery of RNA-
Guided CRISPR/Cas9 Nuclease Complexes Induces Targeted Mutagenesis 
in a Diverse Array of Human Cells, 4 SCI. REP. 1, 5 (2014); see also Elena 
Senís, et al., CRISPR/Cas9-Mediated Genome Engin-eering: An Adeno-
Associated Viral (AAV) Vector Toolbox, 9 BIOTECHNOLOGY J. 1402, 1403 
(2014). See generally Ignazio Maggio, et al., The Emerging Role of Viral 
Vectors as Vehicles for DMD Gene Editing, 8 GENOME MED. 1, 3 (2016). 
103. Joris A. Veltman & Han G. Brunner, De novo Mutations in Human 
Genetic Disease, 13 NATURE REV. GENETICS (2012), 565-75 (Aug. 2012) 
(Box 3). 
104. See generally Puping Liang, et al., CRISPR/Cas9-Mediated Gene Editing 
in Human Tripronuclear Zygotes, 6 PROTEIN & CELL 363 (2015). 
105. See Cyranoski & Reardon, supra note 39. 
106. Liang et al., supra note 104, at 363. 
107. Id., at 364; see also Cyranoski & Reardon, supra note 39. 
108. Id., at 370. 
109. Or any other kind of embryo that is deemed “nonviable.” See Cyranoski 
& Reardon, supra note 39, at 593. 
110. Liang et al., supra note 104, at 364, relying on Balakier H., Tripronuclear 
Human Zygotes: The First Cell Cycle and Subsequent Development. 8 
HUM. REPROD. 1892, 1892-97(1993). 
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The second paper was published on April 6, 2016.111 Yong Fan and 
colleagues, again working with 3PN zygotes, successfully introduced an 
HIV-resistance mutation using CRISPR/Cas9 as a proof-of-principle 
experiment.112 The egg donors provided informed consent and a local 
ethics committee approved the project.113 The latest study, currently 
ongoing by Lu You’s group at Sichuan University, is another world-
first: the group is conducting a clinical trial by injecting a lung cancer 
patient is with cells subjected to TGE by CRISPR/Cas9 to attempt to 
mitigate the cancer.114 A group at Peking University intends to begin 
clinical trials on three other cancers this year.115 
B. The United Kingdom 
On February 1, 2016, the United Kingdom’s Human Fertilisation 
and Embryology Authority (HFEA) approved a research project that 
developmental biologist Kathy Niakan proposed. Her work, aimed to 
understand why pregnancies terminate by manipulating the POU5F1 
gene using CRISPR/Cas9.116 Dr. Niakan’s goal was to “understand the 
genes . . . needed for an embryo to develop into a healthy baby.”117 In 
June 2016, the Cambridge Central Research Ethics Committee, the 
local research ethics board, approved the project.118 The Cambridge 
Central Research Ethics Committee may be thought of as the UK’s 
equivalent of an Institutional Review Board (“IRB”) in the United 
States. An IRB is an oversight mechanism that reviews research 
relating to human subjects.119 
 
111. See Xiangjin Kang, et al., Introducing Precise Genetic Modifications into 
Human 3PN Embryos by CRISPR/Cas-mediated Genome Editing, 33 J. 
ASSISTED REPROD. &GENETICS (2016), 581, 581-88. 
112. See Callaway, Second Chinese Team, supra note 97; See also Kang, supra 
note 111, at 587. 
113. See Callaway, Second Chinese Team, supra note 97; see also Kang, supra 
note 111. 
114. See Cyranoski, supra note 19. 
115. Id. 
116. See Norah M.E. Fogarty et al., Genome Editing Reveals a Role for OCT4 
in Human Embryogenesis, 550 NATURE 67, 74 (2017). 
117. Ethics Committee Greenlights UK Gene Editing, CHRISTIAN CONCERN 
(Jun. 2, 2016), http://www.christianconcern.com/our-concerns/abort
ion/ethics-committee-greenlights-uk-gene-editing. 
118. Lydia Willgress, British Scientist Can Genetically Modify Human 
Embryos, Ethics Committee Says, THE DAILY TELEGRAPH (2016), 
http://www.telegraph.co.uk/news/2016/05/27/british-scientist-can-
genetically-modify-human-embryos-ethics-co/. 
119. To what does this policy apply? See 45 C.F.R. §46.101(a)(2) (2009). 
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The Niakan group published their findings in Nature on September 
20, 2017, showing among other things that transcription factor OCT4120 
plays a role in the formation of the inner cell mass of blastocysts, and 
that downstream genes involved in preimplantation are downregulated 
upon POU5F1 mutation.121 Interestingly, a parallel experiment involving 
mouse embryos yielded significantly different results, suggesting “OCT4 
may be required earlier in human development than in mice[.]”122 The 
group experimented on healthy fertilized embryos donated by couples 
who had undergone IVF and provided informed consent, as well as a 
specific “consent form authorizing the use of genome editing techniques 
including CRISPR-Cas9 on donated embryos.”123 Significantly, the 
informed consent included Niakan’s disclosure that investigators would 
cease the subject embryos’ development before 14 days post-
fertilization.124 This conforms with the “14-day rule,” a policy “line in 
the sand” limitation on in vitro embryo research.125 At or around 14 
days of development the ‘primitive streak’126 forms in the embryonic 
blastula. After this point, “the being in question can no longer be 
anything but a single being [ . . . it] can[not] replicate or divide to form 
another identical being.”127 Embryonic manipulation after this 14-day 
mark is thus considered more ethically dubious than manipulation 
conducted before the mark.128 
 
120. OCT4 is the protein encoded by the POU5F1 gene. See Fogarty et al., 
supra note 116. 
121. Id. 
122. Id. at 72. 
123. Id. at S1. 
124. Id. 
125. See Insoo Hyun, et al., Revisit the 14-Day Rule, 533 NATURE 169, 170 
(2016); See also HEW Support of Research Involving Human In Vitro 
Fertilization and Embryo Transfer, ETHICS ADVISORY BOARD, DEP’T OF 
HEALTH, EDUC., & WELFARE (US Government Printing Office, 1979); See 
also UK DEP’T OF HEALTH & SOCIAL SECURITY, REP. OF THE COMMITTEE 
OF INQUIRY INTO HUM. FERTILISATION AND EMBRYOLOGY 66 (Her 
Majesty’s Stationary Off. Jun. 26 1984) [hereinafter UK Report]. 
126. See Hyun et al., supra note 125, at 170. 
127. HUM. CLONING & HUM. DIGNITY: AN ETHICAL INQUIRY, THE PRESIDENT’S 
COUNCIL ON BIOETHICS 10 (2002), available at https://bioethicsarchive
.georgetown.edu/pcbe/reports/cloningreport/research.html. 
128. Id. at 13. 
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C. Sweden 
In Sweden, Fredrik Lanner’s group at The Karolinska Institute 
(“KI”) has conducted TGE research using healthy human embryos.129 
Dr. Lanner noted in an interview that: 
We applied for and got ethical permits from the Swedish regional 
ethics board (EPN.SE) last spring, 2015. We have also lifted these 
experiments in KI’s internal ethics board, to inform the KI 
leadership of our plans and to make sure we had their support. 
The Swedish law is clear that genome editing is only allowed 
within the first 14 days as long as the embryo is not transferred 
back for a continued pregnancy. This means that heritable 
genome editing for clinical purposes would not be allowed in 
Sweden. The clear legislation has been key in us moving ahead 
with these plans.130 
 Dr. Lanner also noted his funding sources for this work: 
Towards the functional gene studies I have internal funding from 
KI and external funding from the Knut and Alice Wallenberg 
foundation and through Lau fellowship. For our embryo research 
I also have funding from the Swedish Research Council, Ragnar 
Söderberg fellowship and the Swedish Strategic Research 
Foundation.131 
Significantly, the Swedish Research Council is a government agency. 
Thus, it follows that the Swedish government is amenable to funding 
TGE research on human embryos. 
It is not entirely clear what dividends will be seen from these 
research projects. In response to the second Chinese effort to use TGE 
on human embryos, Hokkaido University bioethicist Tetsuya Ishii noted 
that “[i]ntroducing CCR5Δ32 and trying repair, even in nonviable 
embryos, is just playing with human embryos.”132 As to the question of 
using viable embryos, Harvard Medical School biologist and Howard 
Hughes Medical Institute Investigator George Daley cautioned: “the 
study is a landmark, as well as a cautionary tale . . . [t]heir study should 
be a stern warning to any practitioner who thinks the technology is 
ready for testing to eradicate disease genes.”133 
 
129. Lanner Interview, supra note 41. 
130. Id. 
131. Id.(emphasis added). 
132. See Callaway, Second Chinese Team, supra note 97. 
133. See Cyranoski & Reardon, supra note 39. 
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While it may be true that even though experimentation on 
nonviable embryos may be, as Professor Ishii noted, “just playing with 
human embryos,” the proof-of-concept studies are nonetheless ground-
breaking.134 While proof-of-concept research can be met with diminishing 
returns, the lack of federal funding means that fewer U.S. researchers 
will be able to break new ground. Practically speaking, the hands that 
doing the work would become more proficient and with the nuances of 
applying this technology to the human germline. By not federally 
funding TGE directed to embryos, the only American hands becoming 
proficient with the CRISPR/Cas9 system in a human context will be 
supported with private funding. And while utilization in animal models, 
such as mice, zebrafish, and fruit flies, produces immensely valuable 
data and insights, the day may come where the United States must 
take a hard look at the current legal provisions, most notably the 
Dickey-Wicker Amendment, and decide whether the times and 
circumstances dictate a change. 
III. The State of the Debate in the United States: 
Funding, Statutes, and Regulations 
Currently, a number of barriers exist within the United States’ 
existing federal statutory and regulatory scheme, effectively preventing 
federal funding to be allocated toward any TGE usage on human 
embryos. In referring to TGE in human embryos, we are talking about 
manipulation of the germline. Even when new techniques emerge to 
modify the germline using TGE by CRISPR-Cas9, the Federal Food 
and Drug Administration (“FDA”) is prohibited (and has been since 
2015) from entertaining applications of a “drug or biological product” 
resulting from work involving the modification of an embryo.135 When 
taking a hard look at existing policy and, one could readily envision 
two or three competing interests: on one hand, an unquenchable thirst 
for progress and the desire to unlock the secrets of life itself as it exists; 
TGE—embodied most recently by CRISPR-Cas9—represents a 
significant step forward in the quest for that progress. On the other 
 
134. See Callaway, Second Chinese Team, supra note 97. 
135. Public Law 114-113, 114th Cong. (2015), Title VII, § 749(“None of the 
funds made available by this Act may be used to notify a sponsor or 
otherwise acknowledge receipt of a submission for an exemption for 
investigational use of a drug or biological product under section 505(i) of 
the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(i)) or section 
351(a)(3) of the Public Health Service Act (42 U.S.C. 262(a)(3)) in 
research in which a human embryo is intentionally created or modified to 
include a heritable genetic modification. Any such submission shall be 
deemed to have not been received by the Secretary, and the exemption 
may not go into effect.). See also I. Glenn Cohen & Eli Y. Adashi, The 
FDA is Prohibited from Going Germline, 353 SCIENCE 545 (2016). 
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hand, are interests in preserving the sanctity of life, policing the borders 
of what it is to be human, and the old adage of “playing God.” These 
were the same interests at play in the debate over how we regulate 
embryonic stem cells and related research. Does TGE, when utilized 
with human embryos, cross the proverbial Rubicon? It is a close 
question, and perhaps better left to theologians and philosophers. But 
it is important to consider a third interest: TGE may quickly become 
an issue of national security. If we, as a nation, fail to be the first to 
discover and patent136 these technologies, in an intellectual property 
sense, we risk allowing the financial and technological fruits of scientific 
labor to slip through our fingers. By not being the first to invent, we 
may well risk losing the right to lead the inevitably larger, global 
discussion of how to implement these technologies safely, effectively, 
and ethically. 
The first skirmishes on the intellectual property frontier have 
already begun—and with large monetary values at stake. On February 
15, 2017, the Patent Trial and Appeal Board (“PTAB”) held that The 
Broad Institute (of MIT and Harvard), which had filed competing 
patents for CRISPR-Cas9 against the University of California, 
Berkeley, held that The Broad Institute’s patent applications did not 
interfere with UC-Berkeley’s less detailed patent applications; a win for 
Broad.137 Recently, Forbes magazine discussed the consequences of the 
decision (which remains ongoing as of the publication of this Note), and 
estimated the value of an exclusive license for CRISPR-Cas9 at around 
$265 million.138 The licensing of CRISPR-Cas9 itself is being driven in 
to three pipelines: nonexclusive (a) academic or “noncommercial” 
research, or (b) “tools” or “kits” to perform CRISPR-Cas9 editing; or 
exclusive (c) “therapeutics and treatments.”139 Given that scientists are 
 
136. A patent conveys upon a patentee a property right to their invention (35 
U.S.C. § 261), including a right to exclude others from using it (35 U.S.C. 
§ 154(a)(1)), though a patentee may authorize its use through contractual 
license. The lawful use of a U.S. patent would seem more difficult were 
the patentee of foreign origin. The U.S. Government is not directly 
precluded from infringing on a patent right, as the only relief available to 
a patentee under U.S. law is “reasonable and entire compensation” (28 
U.S.C. § 1498(a)) for infringement. 
137. Sharon Begley, Disputed CRISPR Patents Stay with Broad Institute, U.S. 
Panel Says, SCI. AM. (Feb. 15, 2017), https://www.scientificamerican.com
/article/disputed-crispr-patents-stay-with-broad-institute-u-s-panel-
rules/. 
138. Jacob S. Sherkow, How Much Is a CRISPR Patent License Worth?, 
FORBES (Feb. 21, 2017), https://www.forbes.com/sites/jacobsh
erkow/2017/02/21/how-much-is-a-crispr-patent-license-worth/#51f1390
26b77.  
139. Jorge L. Conteras & Jacob S. Sherkow, CRISPR, Surrogate Licensing, 
and Scientific Discovery, 355 SCIENCE 698 (2017). 
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still elucidating the potential of CRISPR-Cas9, and TGE generally, this 
$265 million figure may just be the tip of a very large monetary iceberg. 
It behooves us then, as a nation, to maximize our share of the 
intellectual property that is certain to spring from current and future 
developments. A key first step is to untie our scientists’ hands by 
opening the door to federally funded TGE research on human embryos. 
We, as a nation, still may not be the first to discover the next “game 
changer,” but maximizing our odds is a simple thing to accomplish 
(enabling the funding), if complex to justify. While efforts in the United 
States are proceeding in animal models as articulated above, American 
researchers are only just beginning to conduct human trials.140 China 
and others are now leading the way, and the United States may quickly 
fall behind unless we revisit the kinds of projects which are and are not 
eligible for funding. 
While the promise of TGE includes treating disease and 
understanding basic scientific questions, the specter of eugenics and the 
rise of superhuman “Übermenschen”141 flits about in the background. In 
a critical 2017 Consensus Report from The National Academies of 
Science, Engineering, and Medicine, TGE in clinical research was 
endorsed for therapeutic purposes in both somatic and germline 
contexts—albeit with “caution,” “broad public input,” and “for compelling 
reasons and under strict oversight.”142 As for enhancement, the Consensus  
140. See, e.g., Press Release, Sangamo Therapeutics, Sangamo Announces 
Treatment of First Patient in Landmark Phase 1/2 Clinical Trial 
Evaluating In Vivo Genome Editing for MPS II (Nov. 15, 2017), 
https://investor.sangamo.com/press-releases/detail/381/sangamo-
announces-treatment-of-first-patient-in-landmark (“‘For the first time, a 
patient has received a therapy intended to precisely edit the DNA of cells 
directly inside the body. We are at the start of a new frontier of genomic 
medicine,’ said Dr. Sandy Macrae, CEO of Sangamo therapeutics.”). 
141. “Übermenschen” is the plural form of Übermensch, meaning “The ideal 
superior man of the future who could rise above conventional Christian 
morality to create and impose his own values, originally described by 
Nietzsche in “Thus Spake Zarathustra” (1883–5). Literally, a ‘super-
human person.’ Übermenschen, ENGLISH OXFORD LIVING DICTIONARIES, 
https://en.oxforddictionaries.com/definition/ubermensch (last visited 
Mar. 16, 2017). 
142. 2017 Consensus Report, supra note 101, at 7-8 (Significantly, the 
Consensus Report recommends permitting clinical trials introducing 
heritable changes to the germline only if such a project were to meet a 
number of criteria: “(1) absence of reasonable alternatives; (2) restriction 
to preventing a serious disease or condition; (3) restriction to editing genes 
that have been convincingly demonstrated to cause or to strongly 
predispose to the disease or condition; (4) restriction to converting such 
genes to versions that are prevalent in the population and are known to 
be associated with ordinary health with little or no evidence of adverse 
effects; (5) availability of credible preclinical and/or clinical data on risks 
and potential health benefits of the procedures; (6) ongoing, rigorous 
oversight during clinical trials of the effects of the procedure on the health 
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Report recommends against any such research “at this time.”143 Our 
nation has led the way in many fields of science, and the failure to 
vigorously pursue all avenues of TGE as a matter of government policy 
may cause the United States to lose its edge as a preeminent scientific 
power. If indeed we are on the verge of a new “space race,” the most 
fateful action we can take is no action at all. The rest of the world may 
not be willing to wait for us to parse out the difficult ethical questions 
surrounding this technology. As noted above, the governments of 
China, the UK, and Sweden in particular are taking the lead. As a 
result, the United States risks falling behind in what might well be a 
critical technological revolution of the 21st century. In order to poise 
this nation to win the “Inner Space Race,” we must critically re-examine 
the current legal and regulatory provisions which hamper our progress 
in this area. 
A. The Major Hurdle to Funding TGE Experimentation on Human 
Embryos: The Dickey-Wicker Amendment & NIH Interpretative 
Guidance 
On May 5, 2017, House Resolution 244—the Consolidated 
Appropriations Act, 2017—was codified as Public Law No: 115-31.144 
The 2017 Act, like every appropriations Act since 1996, includes a 
provision that prohibits using any appropriated funding to create a 
human embryo or modify a human embryo “to include a heritable 
genetic modification.”145 Such legislation thus prohibits the use of federal 
funds to support research using CRISPR/Cas9 or another TGE 
technology to modify human germ cells or human embryos. In effect, 
this statutory block digs spurs into a horse which has already left the 
barn. The research will be completed by laboratories eventually, and 
 
and safety of the research participants; (7) comprehensive plans for long-
term, multigenerational follow-up that still respect personal autonomy; 
(8) maximum transparency consistent with patient privacy; (9) continued 
reassessment of both health and societal benefits and risks, with broad 
ongoing participation and input by the public; and (10) reliable oversight 
mechanisms to prevent extension to uses other than preventing a serious 
disease or condition.”). 
143. Id. at 9. 
144. Consolidated Appropriations Act, 2017, Public Law 115-31, §736, 131 
Stat. 135, 173 (in relevant part: “(a) None of the funds made available in 
this Act may be used for— (1) the creation of a human embryo or embryos 
for research purposes; or (2) research in which a human embryo or 
embryos are destroyed, discarded, or knowingly subjected to risk of injury 
or death greater than that allowed for research on fetuses in utero under 
45 CFR 46.204(b) and section 498(b) of the Public Health Service Act (42 
U.S.C. 289g(b)).” §736 incorporates the FDA rider as discussed at supra 
note 135. Public Law 115-31, 115th Cong. (2017), Title VII, §736. 
145. Id. 
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while it is understandable that members of the public may be recalcitrant 
to know their tax dollars might support scientific work involving 
manipulation embryos, for the federal government to remain “dug-in” 
to the horse will only slow it down and engenders the risk of losing our 
edge as the preeminent scientific superpower. During the 2016 election, 
then-candidate Donald J. Trump called for a vast expansion of military 
strength and spending;146 as President, he has proposed a more than 
“10% increase over current spending levels” in our defense budget.147 It 
is clear that the current administration seeks to promote the United 
States in a “position of primacy,” to use the words of Defense Secretary 
James N. Mattis.148 Scientific preeminence is a key arrow in our quiver, 
but the federal prohibition is akin to pulling some of the fletching off 
of that arrow, dulling the arrowhead, or limiting the archer’s draw 
length.149 
The statutory basis for this prohibition lies in the Dickey-Wicker 
Amendment, a bill rider to H.R. 2880, The Balanced Budget 
Downpayment Act of 1995 signed by President Bill Clinton.150 Named 
for its original sponsors—Representatives Jay Dickey (R-AR) and now-
Senator Roger Wicker (R-MS)—the Dickey-Wicker Amendment, found 
at Section 128 of the Act, reads in relevant part: 
 
146. See, e.g., Ashley Parker & Matthew Rosenberg, Donald Trump Vows to 
Bolster Nation’s Military Capacities,  N.Y. TIMES (Sept. 7, 2016) (“We 
want to deter, avoid and prevent conflict through our unquestioned 
military strength.”). 
147. See, e.g., David S. Cloud, Trump Proposes Huge Increase in Military 
Spending, THE L. A. TIMES (Feb. 12, 2018), https://www.latimes
.com/nation/la-na-trump-defense-20180212-story.html. Indeed, President 
Trump proposed a defense budget of $716 billion for FY 2019, a greater 
than $74 billion increase. Compare this spending increase with the NIH’s 
proposed FY 2017 budget of $33.1 billion (see infra note 169). 
148. Id. 
149. Yet another concern is the risk of creating a TGE-directed “medical 
tourism” in the future, wherein individuals, including Americans, seek 
treatments in nations with lax legal and regulatory standards. See 
generally 2017 Consensus Report, supra note 101, at 135-36; see also 
Kenneth W. Abbott et al., Transnational Regulation: Reality or 
Romanticism?, in INTERNATIONAL HANDBOOK ON REGULATING 
NANOTECHNOLOGIES (Graeme A. Hodge et al., eds., 2010); see also R. 
Alta Charo, On the Road (to a Cure?) – Stem-Cell Tourism and Lessons 
for Gene Editing, 374 NEW ENG. J. MED. 901 (2016); I. GLENN COHEN, 
PATIENTS WITH PASSPORTS: MEDICAL TOURISM, LAW, AND ETHICS (Oxford 
Univ. Press, 2015); see also Jeff Lyon, Sanctioned UK Trial of 
Mitochondrial Transfer Nears, 317 J. OF THE AM. MED. ASS’N 462 (2017); 
Leigh Turner & Paul Knoepfler, Selling Stem Cells in the USA: Assessing 
the Direct-to-Consumer Industry, 19 CELL STEM CELL 154 (2016). 
150. See H.R. 2880, 104th Cong. § 128 (1996). 
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None of the funds made available by Public Law 104–91 may be 
used for— 
(1) the creation of a human embryo or embryos for research 
purposes; or 
(2) research in which a human embryo or embryos are destroyed, 
discarded, or knowingly subjected to risk of injury or death 
greater than that allowed for research on fetuses in utero under 
45 CFR 46.208(a)(2) and 42 U.S.C. 289g(b). 
For purposes of this section, the phrase ‘‘human embryo or 
embryos’’ shall include any organism, not protected as a human 
subject under 45 CFR 46 as of the date of enactment of this Act, 
that is derived by fertilization, parthenogenesis, cloning, or any 
other means from one or more human gametes.151  
Subsequent Appropriations Bills have incorporated the Dickey-
Wicker Amendment every year since 1995.152 Thus, the Department of 
Health and Human Services (“HHS”), the supervisory Department over 
the NIH, was, most pertinently, prohibited from disbursing funds for 
the purposes of experimenting directly on human embryos.153 
For example, the Dickey-Wicker Amendment was a focal point of 
the Human Embryonic Stem Cell (“hESC”) debate. In 2009, President 
Obama issued Executive Order 13505—Removing Barriers to Responsible 
Scientific Research Involving Human Stem cells—to overturn the 
George W. Bush-era policy regarding this kind of research.154 Section 2 
of the Executive Order provided that the HHS Secretary (through the 
Director of NIH) may choose to “support and conduct responsible, 
scientifically worthy human stem cell research,”—including hESC 
research,155 and revoked Bush-era limitations that had been in place.156 
On July 11, 2009, the NIH issued revised guidelines which enabled 
federal funding for research projects using hESCs.157 These guidelines 
permitted the funding of research using embryonic stem cells previously 
derived from donor embryos, the embryos provided by individuals 
 
151. Id. 
152. See, e.g., H.R. 1105, 111th Cong. § 509 (2009). 
153. See id. 
154. See Exec. Ord. No. 13,505, 74 Fed. Reg. 46 (Mar. 11, 2009). 
155. Id. 
156. Id. at §5. 
157. Guidelines on Human Stem Cell Research, NAT’L INST. OF HEALTH, 
(2009), https://stemcells.nih.gov/policy/2009-guidelines.htm. . 
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(usually IVF patients) who had donated their embryos freely and with 
their informed consent.158 
That same year, a legal challenge to the policy was raised in what 
became known as Sherley v. Sebelius.159 On April 29, 2011, the United 
States Court of Appeals for the D.C. Circuit held that the NIH’s 
interpretation of the Dickey-Wicker Amendment, as applied to funding 
research involving human embryonic stem cells, was entitled to Chevron 
deference, in view of the federal government’s change in policy.160 In 
Sherley I, scientists James L. Sherley and Theresa Deisher sued to 
enjoin the NIH from funding research using human embryonic stem 
cells. The district court granted a preliminary injunction and the 
government appealed to the D.C. Circuit. The appellate court vacated 
the injunction, finding Dickey-Wicker to be ambiguous, and that the 
NIH’s conclusion was reasonable, because “although Dickey–Wicker 
bars funding for the destructive act of deriving an ESC [line] from an 
embryo, it does not prohibit funding a research project in which an 
ESC [line] will be used.”161 
In applying the first step of the Chevron doctrine to Sherley I, the 
court held that the text was ambiguous as applied to the term 
“research,” and that, in applying the second step, it was reasonable for 
the NIH to interpret Dickey–Wicker as “permitting funding for research 
using cell lines derived without federal funding, even as it bars funding 
for the derivation of additional lines.”162 Sherley I was overturned on 
remand to the D.C. District Court,163 the D.C. Circuit Court overturned 
that decision in Sherley II. Plaintiffs then appealed to the United States 
Supreme Court: on January 7, 2013, the Supreme Court denied 
certiorari, effectively settling the question.164 Thus, after Sherley was 
decided, the ES cell lines themselves, although generated using human 
 
158. Exec. Ord. No. 13,505 at §I. 
159. Sherley & Deisher v. Sebelius, 644 F.3d. 388, 388-90 (D.C. Cir. 2011) 
(hereinafter Sherley I); see also Sherley & Deisher v. Sebelius, 689 F.3d. 
776 (D.C. Cir 2012) (hereinafter Sherley II).  
160. Id. Justice John Paul Stevens, writing for the Court in Chevron U.S.A. 
v. Natural Resources Defense Council, Inc., articulated a two-part test 
for judicial review of administrative construction of statutory language: a 
reviewing court must consider (1) “whether Congress has directly spoken 
to the precise question at issue[,]” and, if Congress had not done so, 
consider (2) “whether the agency’s answer is based on a permissible 
construction of the statute.” If so, the reviewing court would afford the 
agency “Chevron deference.” 467 U.S. 837, 842-44 (1984). 
161. Sherley v. Sebelius, 644 F.3d. 388 at 390 [emphasis added]. 
162. Id., at 394, 396. 
163. Sherley, v. Sebelius, 704 F.Supp.2d 63 (D.D.C. 2010). 
164. Id., cert. denied, 133 S.Ct. 847 (2013). 
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embryos without federal funding, could be used in research projects 
supported by federal funding. 
However, this holding is insufficiently broad to apply and thus 
permit federal funding of using TGE on human embryos, in which the 
research project involves manipulation of a human embryo. Executive 
Order 13505 was limited in scope to “human embryonic stem cell 
research.”165 The key difference is that Executive Order 13505 was 
limited to funding research on hESCs derived from human embryos, not 
research or experimentation on the embryos themselves.166 Therefore, 
Dickey-Wicker still controls with respect to TGE on human embryos, 
and such projects may not be federally funded.167 
B. Federal Funding of Scientific Research: Why it Matters and How it 
is Done 
“It is false to suggest that medical breakthroughs come only 
through government research.” 
-Sen. Roger Wicker168 
 
The NIH is America’s most significant public source of funding for 
biomedical research in the field of life sciences.169 In 2012, public funding 
for biomedical research and development accounted for about 41 
percent of total funds, while private organizations and industry 
accounted for the remaining 59 percent.170 The United States is 
fortunate to have a robust scientific community of passionate 
investigators with diverse research interests. In recent decades, the 
Human Genome Project (“HGP”)171 stands out as a success story: when 
government is willing to get the ball rolling and financially support 
 
165. Exec. Ord. No. 13,505 at §2. 
166. “These guidelines therefore recognize the distinction, accepted by 
Congress, between the derivation of stem cells from an embryo that results 
in the embryo’s destruction, for which federal funding is prohibited, and 
research involving hESCs that does not involve an embryo nor result in 
an embryo’s destruction, for which federal funding is permitted.” NAT’L 
INST. OF HEALTH, GUIDELINES FOR HUMAN STEM CELL RESEARCH (2009). 
167. H.R. 2880, 104th Cong. § 128 (1996). 
168. 152 CONG. REC. 95, 5437 (2006). 
169. See Justin Chakma et al., Asia’s Ascent—Global Trends in Biomedical 
R&D Expenditures, 370 NEW ENG. J. MED. 3, 3 (2014); see also 
Universities Report Continuing Decline in Federal R&D Funding in FY 
2014 NATIONAL SCIENCE FOUNDATION (2015), https://www.nsf.gov/statis
tics/2016/nsf16302/. 
170. Id. at 4. 
171. See generally NAT’L INST. OF HEALTH, GENOME RESEARCH INSTITUTE, All 
About The Human Genome Project (HGP), available at https://www.gen
ome.gov/10001772/all-about-the--human-genome-project-hgp/. 
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research, the scientific community proves more than capable or rising 
to the challenge. During the years of, and immediately following, the 
HGP, the NIH’s overall funding increased steadily, from about $7.6 
billion in 1990 to $31.2 billion in 2010.172 In 2016, NIH’s estimated total 
budget was about $32.3 billion173, with NIH requesting about $33.1 
billion in Congressional appropriations for FY 2017.174 Part of the NIH’s 
stated mission for FY 2017 is to: 
[S]eek fundamental knowledge about the nature and behavior of 
living systems and the application of that knowledge to enhance 
health, lengthen life, and reduce illness and disability. In pursuit 
of this mission, NIH conducts or supports research designed to 
understand the basic biology of human health and disease; apply 
this understanding towards designing new approaches for preven-
ting, diagnosing, and treating disease and disability; and ensure 
that these new approaches are available to all.175 
By its own numbers, “[m]ore than 80% of [NIH] funding” is awarded 
in “almost 50,000 competitive grants to more than 300,000 researchers 
at more than 2,500 universities, medical schools, and other research 
institutions in every state and around the world.”176 The HGP’s extra-
ordinary success answered many questions but, as is often the case with 
empirical science, raises far more. To paraphrase the Roman philosopher 
Cicero: ‘the sinews of war are infinite money.’177 The same argument 
should be made for the sinews of science. 
1. The HGP Corollary: Big Science Works Best when Supported with 
Big Dollars (In this Case, Government Dollars) 
The HGP was inaugurated in 1990. It was an ambitious 
international collaboration of scientists tasked with mapping all genes 
 
172. History of Congressional Appropriations, Fiscal Years 2000-2016, NAT’L 
INST. OF HEALTH (2016), available at https://officeofbudget.od.nih.gov/
pdfs/FY16/Approp%20History%20by%20IC%20FY%202000%20-
%20FY%202016.pdf. 
173. Francis S. Collins, Director, Congressional Justification for F.Y. 2017, NAT’L 
INST. OF HEALTH 1, 3(2016), https://officeofbudget.od.nih.gov/pdfs/FY17
/31-Overview.pdf.. 
174. Id. 
175. Id. at 2. 
176. What We Do: Budget, supra note 37. 
177. MARCUS TULLIUS CICERO, THE FIFTH ORATION OF M.T. CICERO AGAINST 
MARCUS ANTONIUS, OTHERWISE CALLED THE FIFTH PHILIPPIC. (44-43 BC) 
(“[ . . . ] first of all, with the sinews of war, money in abundance [ . . . ]”; 
in the Latin: ‘Nervos belli, pecuniam infinitam’), available at http://www.
perseus.tufts.edu/hopper/text?doc=Perseus%3Atext%3A1999.02.0021%3
Aspeech%3D5. 
Health Matrix·Volume 28·Issue 1·2018 
Shining City on a Hill at the Edge of Tomorrow: CRISPR-Cas9, Dickey-
Wicker, and the Inner Space Race 
500 
that comprise the genome of the Homo sapiens species.178 The United 
States Congress approved a funding scheme for the HGP totaling $3 
billion with an estimated completion date of 2005—or sixteen years—
to facilitate this mapping of the blueprint of life and to affirm the 
nation’s preeminence as an intellectual superpower.179 This was perhaps 
the most significant single federal investment in the field of life sciences, 
and the results were no less significant. Astoundingly, the HGP 
completed two years early (2003) and under budget (about $2.7 
billion).180 It produced an intellectual explosion of novel techniques, 
methods, and especially data.181 
Today, the National Human Genome Research Institute 
(“NHGRI”), operating under the NIH, estimates that “the cost to 
generate a high-quality ‘draft’ whole human genome sequence in mid-
2015 was just above $4,000; by late 2015, that figure [fell] below 
$1,500.”182 Within the next few years, the cost is expected to dip further, 
eventually reaching the idealized “$1000 genome” after which it is 
anticipated that personalized genomic sequencing may become a part 
of standard medical practice.183 The HGP demonstrates that when the 
United States needs scientific progress, government support empowers 
the scientific community to meet and exceed the most ambitious 
expectations. 
When considering the very notion of using taxpayer money to 
support TGE research on embryos, it would be in the public’s best 
interest to support the work which those most in need: namely, TGE 
directed to mitigate or abrogate genetic diseases. This would require an 
examination and prioritization of which projects should receive funding, 
those projects directed to therapeutic intervention for genetic-associated 
disease could receive priority, thus distributing the funds in that such 
 
178. See An Overview of the Human Genome Project, NAT’L HUM. GENOME 
RES. INST., https://www.genome.gov/12011238/an-overview-of-the-
human-%20genome-project/ (last updated May 11, 2017). 
179. The Human Genome Project Completion: Frequently Asked Questions, 
NAT’L HUM. GENOME RES. INST., (2010), available at https://www.genom
e.gov/11006943/human-genome-project-completion-frequently-asked-
questions/.. 
180. Id. 
181. Eric S. Lander et al., Initial Sequencing and Analysis of the Human 
Genome. 409 NATURE 860, 914 (2001). 
182. The Cost of Sequencing a Human Genome, NAT’L HUM. GENOME RES. 
INST., (2016), https://www.genome.gov/27565109/the-cost-of-sequencin
g-a-human-genome/ (using the $4000 figure, the cost to sequence a 
genome today is about 0.00015% of the initial cost of the HGP, or about 
0.000056% using the $1500 figure). 
183. See generally KEVIN DAVIES, THE $1,000 GENOME: THE REVOLUTION IN 
DNA SEQUENCING AND THE NEW ERA OF PERSONALIZED MEDICINE (2010). 
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a way that is both compassionate and goal-oriented. To achieve that, 
it is necessary to examine the standards of review, and why they should 
be further refined in view of the TGE revolution. We examine these 
issues in the next section. 
2. The Present Regulatory Framework is Insufficient to Accommodate 
TGE Research on Human Embryos 
a. From Grant Application to Bench: Initial and Ongoing Review and 
Oversight 
A typical grant application to the NIH must pass two separate 
levels of peer review before being recommended for funding. First, a 
Scientific Review Group (SRG), made up of non-federal scientists with 
expertise in scientific research, reviews the grant application.184 Next, 
the research must be approved by the National Advisory Council of the 
Institute and Center (IC). Scientific and non-scientific citizens who 
have demonstrated prowess in health and disease-related issues make 
up this second step of peer review.185 A grant application must be 
approved by steps one and two before receiving a recommendation for 
funding, which would then be approved by IC Directors.186 Thus, a 
researcher who wants to conduct biological research using NIH funding 
must first pass the two NIH levels of peer review. Once NIH Funding 
is Obtained for a Human Study, a Research Laboratory is Subject to 
Ongoing Oversight by an Institutional Review Board (IRB).187 With 
respect to ongoing research involving human subjects, a Congres-
sionally-authorized National Commission for the Protection of Human 
Subjects of Biomedical and Behavioral Research issued the Belmont 
Report in 1979.188 The Belmont Report provided a number of recom-
mendations guiding the ethical conduct of research involving human 
subjects.189 Regulations grew out of these recommendations and 
 
184. Peer Review, NAT’L INST. OF HEALTH, OFF. OF EXTRAMURAL RES., 
https://grants.nih.gov/grants/peer-review.htm (last visited Mar. 17, 
2017). 
185. Id. 
186. Id. 
187. See Basic HHS Policy for Protection of Human Research Subjects 45 
C.F.R. §46, Subpart A (2009). 
188. The Belmont Report, THE NAT’L COMMISSION FOR THE PROTECTION OF 
HUM. SUBJECTS OF BIOMEDICAL & BEHAVIORAL RES., (Apr. 18, 1979), 
available at https://www.hhs.gov/ohrp/sites/default/files/the-belmont-
report-508c_FINAL.pdf. 
189. Id. 
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numerous federal agencies adopted them,190 including HHS.191 Today, 
the ensuing body of regulations is better known as the “Common 
Rule.”192 The Common Rule establishes the IRB, a committee com-
prising at least five members of varying and diverse backgrounds.193 The 
function of an IRB is: 
[T]o promote complete and adequate review of research activities 
commonly conducted by the institution . . . to promote respect 
for its advice and counsel in safeguarding the rights and welfare 
of human subjects . . . to ascertain the acceptability of proposed 
research in terms of institutional commitments and regulations, 
applicable law, and standards of professional conduct and 
practice . . . . [i]f an IRB regularly reviews research that involves 
a vulnerable category of subjects, such as children . . . consid-
eration shall be given to the inclusion of one or more individuals 
who are knowledgeable about and experienced in working with 
these subjects.194 
The IRB thus serves as an intra-institutional check on research 
programs involving human subjects.195 It relies on both scientific 
expertise and regulatory compliance to foster, in the words of the 
Belmont Report, “the basic ethical principles that should underlie the 
conduct of biomedical and behavioral research involving human 
subjects.”196 
The 2009 NIH Guidelines on Human Stem Cell Research,197 with 
respect to the Common Rule, recite that “IRB review may be required” 
in certain circumstances, for “certain research involving [human 
Embryonic Stem Cells] hESCs.”198 The rationale is that “[t]he HHS 
 
190. See MAXWELL J. MEHLMAN, TRANSHUMANIST DREAMS AND DYSTOPIAN 
NIGHTMARES: THE PROMISE AND PERIL OF GENETIC ENGINEERING 174-76 
(2012). 
191. U.S. DEP’T OF HEALTH AND HUM. SERV., OFF. FOR HUM. RES. 
PROTECTIONS, Federal Policy for the Protection of Human 
Subjects (‘Common Rule’), https://www.hhs.gov/ohrp/regulations-
and-policy/regulations/common-rule/ (last visited Mar. 17, 2017). 
192. Id.; The Belmont Report, supra note 188. See also Basic HHS Policy for 
Protection of Human Research Subjects 45 C.F.R. §46, Subpart A (2009). 
193. See Basic HHS Policy for Protection of Human Research Subjects, 45 
C.F.R. § 46, Subpart A 
194. Id. 
195. Id. 
196. The Belmont Report, supra note 188; see also Basic HHS Policy for 
Protection of Human Research Subjects 45 C.F.R. §46, Subpart A (2009). 
197. Collins Statement, supra note 38. 
198. Id. at Section 9, Subsection I., Paragraph 3. 
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Office for Human Research Protections (“OHRP”) considers biological 
material, such as cells derived from human embryos to be individually 
identifiable . . . ”199 A similar rationale might support the case of TGE 
and human embryos: an intra-institutional check through the IRB is 
important to protect the privacy rights of embryo donors, including 
obtaining donors’ informed consent.200 This ethical check could continue 
to serve as an appropriate concurrent oversight mechanism for projects 
featuring TGE directed to embryos, once funded. Since the donors 
supply the fertilized, cryopreserved eggs—the “extras” of an IVF 
procedure—OHRP regulations require obtaining and documenting 
informed consent from prospective donors.201 
b. Additional Oversight through the FDA and DAC. 
Additional layers of regulatory oversight exist in addition to the 
grant application review process. The FDA, in interpreting its statutory 
authority under the Federal Food, Drug, and Cosmetic Act (“Act”), 
determined in 1993 that the Act’s definitions of “biological product” 
and “drug” was sufficiently broad to encompass products that would 
eventually emerge from the research into “somatic cell and gene 
therapies.”202 Similarly, the NIH maintains a federal Recombinant DNA 
Advisory Committee (“RAC”) to advise the NIH Director about 
“recombinant or synthetic nucleic acid molecules.”203 The scope of 
 
199. Id. 
200. See Human Embryo Research, COMM. ON PEDIATRIC RES. AND COMM. ON 
BIOETHICS, AM. ACAD. OF PEDIATRICS (Sep. 2001), available at 
http://pediatrics.aappublications.org/content/108/3/813. 
201. 45 C.F.R. § 46.111 (4-5) (2009). 
202. U.S. Food and Drug Administration, Application of Current Statutory 
Authorities to Human Somatic Cell Therapy Products and Gene Therapy 
Products, 58 Fed. Reg. 53248 (1993). 
203. The establishment of the RAC by the NIH director is authorized under 
The Public Health Service Act of 1944 § 402(b)(16), 42 U.S.C. 
§ 282(b)(16): “[ . . . ]the Secretary [of HHS], acting through the Director 
of NIH [ . . . ] may, [ . . . ] establish such technical and scientific peer 
review groups and scientific program advisory committees as are needed 
to carry out the requirements of this subchapter and appoint and pay the 
members of such groups [ . . . ].” See DEP’T OF HEALTH AND HUM. SERV., 
NAT’L INST. OF HEALTH, CHARTER: RECOMBINANT DNA ADVISORY 
COMMITTEE (Jun. 30, 2017)(“Objectives and Scope of Activities: The 
Committee will provide advice to the Director, National Institutes of 
Health (NIH), on matters related to ( 1) the conduct and oversight of 
research involving recombinant DNA, including the content and 
implementation of the NIH Guidelines for Research Involving Recombinant 
or Synthetic Nucleic Acid Molecules (NIH Guidelines), as amended, and 
(2) other NIH activities pertinent to recombinant or synthetic nucleic acid 
technology. There will be a continuing need for the Committee to serve 
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review would also encompass TGE as applied to human embryos. As of 
April 2016, RAC reviews gene transfer204 protocols that institutional 
oversight bodies, such as IRBs or Institutional Biosafety Committees 
(“IBCs”) refer to it.205 Additionally, at least one of the following must 
be satisfied to trigger RAC review: 
a. The protocol uses a new vector, genetic material, or delivery 
methodology that represents a first-in-human experience, thus 
presenting an unknown risk; 
b. The protocol relies on preclinical safety data that were obtained 
using a new preclinical model system of unknown and uncon-
firmed value; or 
c. The proposed vector, gene construct, or method of delivery is 
associated with possible toxicities that are not widely known and 
that may render it difficult for oversight bodies to evaluate the 
protocol rigorously.206 
It is important to note here that, currently, the IRB or IBC must 
refer the study to RAC for review. However, were the NIH Guidelines 
appropriately revised, we could “bring back the RAC”207 as the primary 
oversight body for NIH-funded gene transfer experiments generally, or 
perhaps specifically for TGE directed to human embryos. An expansion 
 
these functions so long as the NIH supports activities involving 
recombinant or synthetic nucleic acids.”). 
204. “Gene transfer” means “the deliberate transfer into human research 
participants of either recombinant nucleic acid molecules, or DNA or RNA 
derived from recombinant nucleic acid molecules, or synthetic nucleic acid 
molecules.” Biomedical Technology Assessment: Oversight of Human 
Gene Transfer Research NAT’L INST. OF HEALTH, OFF. OF SCI. POL’Y, 
http://osp.od.nih.gov/office-biotechnology-activities/biomedical-technolo
gy-assessment/hgt (last visited Mar. 17, 2017). See also UCI Office of 
Research, Human Gene Transfer Research, https://research.uci.edu
/cascade/compliance/human-research-protections/researchers/human-ge
ne-transfer-research.html (last visited Apr. 9, 2018). 
205. Charter Recombinant DNA Advisory Committee, DEP’T. OF HEALTH & 
HUM. SERV. (May 22, 2017), available at https://osp.od.nih.gov/wp-con
tent/uploads/RAC_Charter_2017_508.pdf. 
206. FAQ: Registration and Review Process for Human Gene Transfer 
Protocols, NIH, http://www.osp.od.nih.gov/sites/default/files/FAQs%2
0on%20the%20NIH%20Review%20Process%20for%20Human%20Gene%2
0Transfer%20Trials%20%28October%202016%29.pdf (last visited Jan. 22, 
2017). 
207. E.g, Helen Thompson, After 40 Years, Fate of Recombinant DNA 
Committee Under Review, 19 NATURE MED. 1074 (2013) (“But the RAC 
now faces a potential reduction or modification of its powers [ . . . ]”). 
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of the RAC might serve well to examine the ethical implications of TGE 
research on embryos. 
As illustrated above, there are considerable ethical implications to 
such research. But as the United States risks lagging behind other 
countries that embracing government-funded TGE research on 
embryos, the impetus to progress in this field warrants a measure of 
urgent expediency, and it should be enshrined as government policy. It 
is therefore imperative that, despite the ethical oversight that exists 
within the NIH vetting process for grant applications, the federal 
government should provide the means for an adequate hearing of 
opposing views. 
The next section proposes changes to Dickey-Wicker—either 
through NIH promulgating new interpretive guidance of the amendment 
or amending the statute itself—in addition to a novel plan for an 
additional, two-tiered system of ethical oversight and review of potential 
projects that would be considered for federal funding under a permissive 
policy of TGE research on embryos. 
Interlude: The Soviet Union Wins Round Two of the 
Space Race 
On April 12, 1961, aboard his 5-ton Vostock I spacecraft, 
Cosmonaut Yuri Gagarin became the first human being to orbit the 
Earth.208 Although American astronaut Alan Shepard achieved the 
same feat aboard Freedom 7 less than a month later,209 the United 
States remained profoundly behind their great rival in the Space Race; 
the Soviet Union had won round two. Newsweek, in an aptly titled 
article “Why We’re Behind—Will We Catch Up?”210 pondered whether 
the first man on the moon would “carry the hammer and sickle.”211 
Undeterred, President Kennedy, in a speech before a joint session of 
Congress, made it a national priority “before this decade is out, of 
landing a man on the moon and returning him safely to the Earth.”212 
NASA’s budget increased by 89 percent that year, and increased 
 
208. A History of Human Spaceflight, NASA, https://www.nasa.gov/topics
/history/features/gagarin/gagarin.html (last visited Mar. 28, 2018). 
209. May 5, 1961 to be exact. See David Hitt, Who Was Alan Shepard?, NASA 
(May 11, 2011), https://www.nasa.gov/audience/forstudents/k-4/stori
es/nasa-knows/who-was-alan-shepard-k4.html.  
210. Why We’re Behind—Will Catch Up?, NEWSWEEK: THE VOYAGE—
SPECIAL SECTION (Apr. 24, 1961), available at 
http://www.newsweek.com/april-24-1961-us-response-yuri-gagarin-1860.  
211. Id. 
212. John F. Kennedy, Special Message to the Congress on Urgent National 
Needs, AM. PRESIDENCY PROJECT (May 25, 1961), 
http://www.presidency.ucsb.edu/ws/?pid=8151.  
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another 101 percent the next.213 In his now-famous address at Rice 
Stadium in Houston, Texas that next year, Kennedy said in part: 
We choose to go to the moon. We choose to go to the moon in 
this decade and do the other things, not because they are easy, 
but because they are hard, because that goal will serve to 
organize and measure the best of our energies and skills, 
because that challenge is one that we are willing to accept, one 
we are unwilling to postpone, and one which we intend to win, 
and the others, too.214 
It is precisely because the questions surrounding the current subject 
of TGE are hard, that we should choose to pursue them, to accept the 
challenges and confront them, head on. For if we do not, we leave the 
door open for others to answer them for us. 
IV. Recommendations 
This Section provides putative recommendations for the federal 
government to begin to open the door to embryonic research, specifically 
as applied to TGE. These recommendations recognize the primacy of 
TGE for therapeutic ends, in accordance with The National Academies 
Consensus Report discussed in Section II.215 I propose reinterpreting or 
amending the Dickey-Wicker text to expand permissible funding to 
some or all human embryos obtained from donors with informed consent, 
while simultaneously advocating for interdepartmental and interdisci-
plinary ad hoc committees to specifically and unambiguously lay out 
the reasonable ethical boundaries of frontier research and, significantly, 
prioritize and favor funding those conditions most detrimental to public 
health, or possibly single gene disorders.216 We explore these options 
below. 
 
213. John M. Logsdon, John F. Kennedy and NASA, NASA (Aug. 7, 2017), 
https://www.nasa.gov/feature/john-f-kennedy-and-nasa. 
214. John F. Kennedy, President of the United States, speech at Rice Stadium 
(Sep. 12, 1962), available at https://er.jsc.nasa.gov/seh/ricetalk.htm. 
215. See 2017 Consensus Report, supra note 101. 
216. The National Academies’ Consensus Report lists several potential 
therapeutic applications for somatic cell TGE, including sickle-cell disease, 
-thalassemia, X-linked severe combined immunodeficiency, hemophilia B, 
cystic fibrosis, HIV, Deuhenne’s muscular dystrophy, Huntington’s 
disease, etc., which could also form the basis for embryonic research 
priorities. Id. at 92-93; see also Diseases Treated by Gene Therapy, supra 
note 91. 
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A. Reinterpreting or Reevaluating Dickey-Wicker 
As mentioned in Part IV.B., federal funding is the largest source of 
research funding for life sciences in the United States and currently, 
there is a prohibition on funding as applied to TGE on human 
embryos.217 In order to meliorate this, the federal government could 
either permit federal funds to support TGE research on nonviable 
embryos,218 or permit federal funds to support research on both viable 
and nonviable embryos.219 The first option might be the more promising 
option in the short term, because the Dickey-Wicker Amendment’s 
statutory text could simply be amended with the addition of a single 
word, so as to permit such funding. The textual change may be simple, 
but it is profound and, again, the political hurdles are complex and 
challenging. Although some have suggested an outright repeal of 
Dickey-Wicker,220 such a drastic shift from established congressional 
policy is unlikely to gain much political traction in the near future. 
A more politically feasible option might be for Congress to amend 
Dickey-Wicker and carve out exceptions, as was done during the stem 
cell debate.221 Such exceptions, as the one proposed by George Annas,222 
would keep the creation of embryos for the purposes of research within 
the scope of prohibition, while enabling funding to support the actual 
research itself. The creation of the embryo remains the decision of the 
couple undergoing IVF, and preserves their decision-making autonomy: 
namely, the couple giving their informed consent to scientists who want 
to use for research those embryos not used specifically for implantation. 
This could allay public concern regarding the notion that scientists 
would be “creating” embryos—or life—solely for the purposes of 
research. Briefly, IVF is an assisted reproductive technology (“ART”) 
that achieves fertilization artificially and outside of the body (in 
 
217. H.R. 2029, 114th Cong. §§ 508, 749 (2015); see also H.R. 2880, 104th 
Cong. § 128 (1996). 
218. See Liang, supra note 104. 
219. This option would likely manifest as an outright repeal of Dickey-Wicker. 
220. See, e.g., Don C. Reed, Repeal Dickey-Wicker: Time to Stop Renewing 
the Anti-Research Law, THE HUFFINGTON POST (Nov. 9, 2010), 
https://www.huffingtonpost.com/don-c-reed/remove-dickeywicker-time-
_b_780071.html. 
221. See, e.g., George J. Annas, Resurrection of a Stem-Cell Funding 
Barrier—Dickey-Wicker in Court, 363 NEW ENG. J. MED. (2010), 1687, 
1689. (Here, Annas proposes amending Dickey-Wicker by adding a 
provision reading: “[n]othing in part (2) prohibits the NIH from funding 
research using embryos created for procreation, including the derivation 
of stem cells, when the couple no longer wants to use them for procreation 
and has provided their informed authorization for them to be used in NIH-
funded research [emphasis added].”) 
222. Id. 
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vitro).223 Fertilized eggs, called zygotes, divide and become embryos.224 
The embryo may then be transferred into the woman’s womb or frozen 
for later implantation or donation.225 Alternatively, the text of Dickey-
Wicker could be amended so that subsection (a)(2) of the amendment 
adds the word “viable” to the term “human embryo.” Doing so would 
unambiguously carve out an exception for research on nonviable human 
embryos, which would at least enable some projects. Each of these 
alternatives is explored below. The text of Dickey-Wicker could also 
further be amended to at last explicitly incorporate something akin to 
the 14-day-rule into the text as an exception to the funding prohibition, 
in order to impose a developmental time-limitation on subsequent 
research projects.226 The 14-day rule, first proposed in the United States 
in 1979, specifies that “[ . . . ]no embryos will be sustained in vitro 
beyond the stage normally associated with the completion of 
implantation (14 days after fertilization) [ . . . ]” 227. Furthermore, the 
United Kingdom’s Warnock Committee endorsed the 14-day rule five 
years later,228 and as of 2016 is codified into law in 12 countries.229 While 
there have been proposals to extend the 14-day rule (to 21-days, for 
 
223. In Vitro Fertilization (IVF), U.S. NAT’L LIBR. OF MED.: MEDLINE PLUS, 
https://medlineplus.gov/ency/article/007279.htm (last visited Apr. 8, 
2018) [hereinafter IVF]. 
224. FAQ: How Does a Fertilized Egg Develop?, NATURE, http://www.nature.c
om/stemcells/2007/0706/070614/full/stemcells.2007.13.html (last visited 
Jan. 30, 2018). 
225. IVF, supra note 223. 
226. Hyun, et al, supra note 125. 
227. ETHICS ADVISORY BOARD, DEP’T OF HEALTH, EDUC., AND WELFARE, REP. 
AND CONCLUSIONS: HEW SUPPORT OF RES. INVOLVING HUM. IN VITRO 
FERTILIZATION AND EMBRYO TRANSFER 107 (U.S. Gov’t Printing Off. May 
4, 1979); see also Hyun et al., supra note 125, at 170. 
228. “We accordingly recommend that no live human embryo derived from in 
vitro fertilisation, whether frozen or unfrozen, may be kept alive, if not 
transferred to a woman, beyond fourteen days after fertilisation, nor may 
it be used as a research subject beyond fourteen days after fertilisation. 
This fourteen day period does not include any time during which the 
embryo may have been frozen.” UK Report, supra note 125, at 66. 
229. Hyun et al., supra note 125, at 170-71. The nations which have codified 
into law some variant of the 14-day rule include Australia, Canada, 
Denmark, Iceland, the Netherlands, New Zealand, Slovenia, South Korea, 
Spain, Switzerland, Switzerland (7 days), and the United Kingdom. But 
it is worth noting that “[t]he 14-day rule was never intended to be a bright 
ling denoting the onset of moral status in human embryos. Rather, it is a 
public-policy tool designed to carve out a space for scientific inquiry and 
simultaneously show respect for the diverse views on human-embryo 
research.” Id. at 170. 
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example),230 the notion of a strict developmental time restriction on 
embryonic research represents a reasonable balance between enabling 
embryonic research and acknowledging public concerns; it has been 
employed in other countries, and is certainly worth considering.231 
B. NIH Guidance Should Interpret Dickey-Wicker to Permit TGE That 
Uses Nonviable Human Embryos 
Yet another suggestion—as a possible first step—would be for the 
NIH to reinterpret the statutory language to exempt nonviable embryos 
from the funding prohibition, and revise its Guidelines to reflect that 
reinterpretation. In so doing, it would thus be useful to analyze Dickey-
Wicker in its entirety under the Chevron framework, using the 
reasoning of the to what the D.C. Circuit in Sherley I as a template, to 
determine whether, first, if Congress had spoken to the precise question 
at issue relating to TGE in nonviable human embryos and second, if it 
had not done so, whether an interpretation of the text to permit some 
or all of the experiments contemplated above would constitute a 
reasonable or permissive interpretation of the statute.232 In Sherley I, 
the majority adopted a narrow reading of the word “research,” as there 
was “no basis for th[e] inference” to read it more broadly as urged by 
the plaintiffs.233 Because of this narrow interpretation, the majority 
ultimately found the text of Dickey-Wicker to be ambiguous, and thus 
proceeded to step two of the Chevron analysis.234 Subsection (a)(1) 
prohibits federal funds from supporting research that contemplates the 
“creation of a human embryo or embryos for research purposes.” 235 The 
United States’ current practice regarding derivation of embryonic stem 
cell lines permits acquisition of embryos from donors who underwent 
IVF treatment with their informed consent.236 The act of in vitro 
 
230. See, e.g., John Harris, It’s Time to Extend the 14-Day Limit for Embryo 
Research, THE GUARDIAN (May 6, 2016). 
231. For example, we could amend the text of subsection (a)(2) of Dickey-
Wicker to read: “(a) None of the funds made available in this Act may be 
used for—[ . . . ] (2) research in which a human embryo or embryos are 
destroyed, discarded, or knowingly subjected to risk of injury or death 
greater than that allowed for research on fetuses in utero under 45 CFR 
46.208(a)(2) and Section 498(b) of the Public Health Service Act (42 
U.S.C. 289g(b)) (Title 42, Section 289g(b), United States Code) after 14 
days post-fertilization (emphasis added).” 
232. See Chevron, 467 U.S. at842-44.. 
233. Sherley v. Sebelius, 644 F.3d. 388 at 394. 
234. Id. 
235. H.R. 2880, 104th Cong. § 128 (1996). 
236. Exec. Ord. No. 13,505 at §I (“The Guidelines allow for funding of research 
using hESCs derived from embryos created using in vitro fertilization 
(IVF) for reproductive purposes and no longer needed for these purposes, 
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fertilization is the “creation of a human embryo[.]”237 This explains, in 
part, why government health insurance programs like Medicaid do not 
cover IVF treatments,238 and why many people seeking IVF will have 
to pay out-of-pocket for the procedure.239 IVF-generated embryos from 
donors form the bulk of the embryos utilized to generate stem cell lines 
and the like. Scientists could perform similar TGE studies with donor 
embryos. Therefore, a TGE project hypothetically funded by federal 
sources need not require that the researcher create their own embryos: 
researchers can obtain them from IVF donors with informed consent, 
as is done for stem cell line derivation.240 This piece—that is, Dickey-
Wicker subsection (a)(1)—is no different from the currently-funded 
research on stem cells, except that the stem cell lines have technically 
been derived from embryos separately from the downstream, federally 
funded, research. But with TGE on embryos, the research is being 
performed on the embryos themselves. 
The challenge is in Subsection (a)(2).241 It follows that after a TGE 
experiment in which the experimental embryos are not implanted into 
a uterus, the experimental embryos would be destroyed. The UK and 
Sweden pioneer studies both operate under a legal framework that 
require this.242 However, if Dickey-Wicker intended to promote a culture 
of life, then perhaps nonviable embryos—those which are incapable of 
developing into a human—would not fit into this category. The Huang 
group (China), in their seminal publication, employed tripronuclear 
zygotes in their study demonstrating CRISPR/Cas9 editing of human 
embryos.243 The tripronuclear zygotes consist of “one oocyte nucleus 
 
assuming the research has scientific merit and the embryos were donated 
after proper informed consent was obtained from the donor(s).”). 
237. See H.R. 2880, 104th Cong. § 128 (1996). 
238. Medicaid Coverage & Fertility Treatment, UNIV. OF COLORADO, https://a
rm.coloradowomenshealth.com/resources/medicaid-fertility-treatments/ 
(last visited Mar. 16, 2017). 
239. Couples and individuals seeking fertility treatment might pay anywhere 
from $10,000 to more than $60,000 out of pocket. See, e.g., Nina Bahadur, 
The Cost of Infertility: This is How Real People Pay for IVF, SELF (Jan. 
8, 2018), https://www.self.com/story/the-cost-of-infertility. 
240. See, e.g., Stem Cell Research: Embryo Donation, UNIV. OF MICH., 
http://www.stemcellresearch.umich.edu/donation/donors.html (last vis-
ited Mar. 16, 2017). 
241. Prohibiting federal funds for “(2) research in which a human embryo or 
embryos are destroyed, discarded, or knowingly subjected to risk of injury 
or death greater than that allowed for research under [applicable Federal 
regulations] . . . ” H.R. 2880, 104th Cong. § 128 (1996). 
242. Fogarty, supra note 116, at S1; see also Lanner Interview, supra note 41. 
243. See Liang et al., supra note 104. See also David Cyranoski & Reardon, 
supra note 39. 
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and two sperm nuclei”244 and would not likely result in a live birth, even 
if later implanted in a uterus. Thus, IVF procedures screen against 
embryos having aneuploidy (including triploidy).245 Contrast the 
scenario of modifying a nonviable embryo with modifying a viable one 
(that is, capable of developing into a full-grown human). If the 
nonviable embryo were implanted in a uterus, then, it would not 
develop into a fetus; in other words, there is no potential for life from 
the get-go.246 Indeed, if researchers used only nonviable, tripronuclear 
embryos for their experiments, one could even argue that the “creation” 
of tripronuclear zygotes, inherently incapable of life, may be permissible 
with respect to provision (1) of Dickey-Wicker. These issues a very 
narrow line on defining “life,” or “an organismic state characterized by 
capacity for metabolism, growth, reaction to stimuli, and reproduction.”247 
Such properties are not ascribed to a nonviable embryo.248 Thus, in 
applying Chevron’s second step, a court could reasonably conclude that 
a “permissible interpretation” of the decidedly ambiguous wording of 
the statute249 could encompass nonviable embryos. If the NIH chose to 
do so, it might well revise their Guidelines to render nonviable embryos 
permissible for federally-funded TGE research. This reasoning would 
appear to be in tandem with the D.C. Circuit’s holding in Sherley I, in 
which it agreed with the government’s position and reliance on the 2009 
NIH Guidelines which “expressly distinguished” between the derivation 
of ESCs and “research involving [ESCs] that does not involve an 
embryo nor result in an embryo’s destruction” [ . . . ] mak[ing] clear the 
agency’s understanding that ‘research involving [ESCs]’ does not 
 
244. Id., at 364. 
245. See, e.g., Preimplantation Genetic Screening, ADVANCED FERTILITY CTR. 
CHI., https://www.advancedfertility.com/pgs-ivf-genetic-testing.htm 
(last visited Mar. 28, 2018). 
246. Except, perhaps, from TGE methods or experiments which could restore 
or impute viability to an otherwise nonviable embryo. In such a case, the 
resultant, TGE-modified embryo would go from being inherently 
nonviable to becoming viable. See, e.g., Cyranoski & Reardon, supra note 
39. 
247. Definition of Life, MERRIAM-WEBSTER DICTIONARY, available at 
http://www.merriam-webster.com/dictionary/life (last updated Jan. 25, 
2018). 
248. See Wolfe v. Isbell, 208 So.2d 758, 759 (Ala. 1973) (“By nonviable we 
mean not capable of living, growing, or developing and functioning 
successfully, the antithesis of viable, which is defined as having attained 
such form and development of organs as to be normally capable of living 
outside the uterus.”). See Mack v. Carmack, 79 So.3d 597, 602, 606 (Ala. 
2011) (recognizing the abrogation). 
249. E.g., Sherley v. Sebelius, 644 F.3d. 388. 
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necessarily include the antecedent process of deriving cells.”250 This 
reasoning is consistent with Clinton HHS General Counsel Harriet 
Rabb’s determination that “federally funded research that utilizes 
hPSCs [human pluripotent stem cells] would not be prohibited by the 
HHS appropriations law prohibiting human embryo research, because 
such cells are not human embryos (emphasis added).”251 But herein is 
the critical question: are nonviable embryos, particularly tripronuclear 
embryos, still considered “human embryos?” 
It would appear so. Subsection (b) of Dickey-Wicker provides the 
answer: “the term ‘human embryo or embryos’ includes any organism, 
not protected as a human subject[ . . . ]that is derived by fertilization, 
parthenogenesis, cloning, or any other means from one or more human 
gametes or human diploid cells.”252 Tripronuclear embryos—and all 
aneuploid embryos for that matter—are still the result of fertilization: 
sperm and egg, and would thus qualify as a human embryo under the 
defined term. Although tripronuclear embryos are not entirely rare,253 
the prognosis is almost universally grim, nearly always resulting in 
miscarriage.254 This is why abnormally fertilized oocytes are not 
transferred in IVF procedures.255 But since there is a potential for live 
birth, tripronuclear embryos would not, strictly speaking, be thought 
of as inherently nonviable. While the Supreme Court of the United 
States has yet to issue a ruling on the personhood of a nonviable 
embryo, some states have distinguished nonviable embryos from viable 
embryos: for example, Louisiana defines a nonviable embryo as an 
 
250. Sherley v. Sebelius, 644 F.3d. 388 at 396 (quoting NIH 2009 Guidelines, 
74 Fed.Reg. 32, 172/2). 
251. National Institutes of Health Guidelines for Research Using Human 
Pluripotent Stem Cells, 64 Fed. Reg. 51795, 51976 (Aug. 25, 2000). 
252. Consolidated Appropriations Act, 2017, Pub. L. No. 115-31, § 508(b), 131 
Stat. 135, 563 (2017); see also O. Carter Snead, Science, Public Bioethics, 
and the Problem of Integration, 43 U.C. DAVIS L. REV. 1529, 1547 note 76 
(“Accordingly, there is strong support for the proposition that a blastocyst 
is clearly an individuated organism, that is, a whole, individual member 
of the human species.”). 
253. Triploidy is thought to occur in 2-3% of pregnancies, often resulting in 
spontaneous abortion, but “occasionally results in the fetal or newborn 
period with the birth of an abnormal fetus or infant.” D.E. McFadden & 
W.P. Robinson, Phenotype of Triploid Embryos, 43 J. MED. GENETICS 
609, 609 (2006). 
254. Abnormally Fertilised Embryos in IVF Biology Essay, UKESSAYS (March 
23, 2015), https://www.ukessays.com/essays/biology/abnormally-fertilise
d-embryos-in-ivf-biology-essay.php.  
255. Id.; see also Katie Feenan & Mary Herbert, Can ‘Abnormally’ Fertilized 
Zygotes Give Rise to Viable Embryos?, 9 HUM. FERTILITY 157, 164 (2006). 
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embryo that is not “considered a juridical person.”256 While not federally 
authoritative, such distinctions might help establish a fundamental 
distinction between viable and nonviable embryos. But assuming, 
arguendo, that the tripronuclear embryos from IVF would still fit the 
definition of “human embryo,” the Dickey-Wicker text, as written, 
would not inherently exempt these embryos from the funding 
prohibition. What is left? The only remaining category of embryos that, 
strictly speaking, are nonviable are those “deemed to have ‘arrested 
irreversibility[,]’” 257 which have been shown as a potential source for 
ESC derivation.258 These embryos would have to be empirically 
examined after fertilization to determine whether they are, in fact, 
nonviable. In such a case, the potential for life in these ‘dead’ embryos 
is zero. 
C. Congress Should Amend Dickey-Wicker to Limit the Prohibition of 
Federal Funds to ‘Viable’ or ‘Diploid’ Human Embryos 
An alternative option to the one discussed in the preceding 
subsection would be for Congress to amend Dickey-Wicker by 
introducing a minor but profound change to the language of the statute 
that would qualify the viability of embryos so currently prohibited.259 
 
256. LA. STAT. ANN. § 9:129 Destruction (“A viable in vitro fertilized human 
ovum is a juridical person which shall not be intentionally destroyed by 
any natural or other juridical person or through the actions of any other 
such person. An in vitro fertilized human ovum that fails to develop 
further over a thirty-sixhour period except when the embryo is in a state 
of cryopreservation, is considered nonviable and is not considered a 
juridical person.”). See also Jeter v. Mayo Clinic Arizona, 121 P.3d 1256, 
1261 (App. App. Div. 1 2005). But see, e.g., People v. Kurr 654 N.W.2d 
651, 654 (Mich. App. 2002). 
257. Asma Shaikh, Dead Embryos Give Life, ISSUES BERKELEY MED. J. AT UC 
BERKELEY (2007), https://www.ocf.berkeley.edu/~issues/articles/14.2_S
haikh_A_Dead_Embryos_1.html (“meaning the blastomeres had not 
undergone any cleavage division for at least 24 to 48 hours after con-
ception[ . . . ] so-called dead embryos[ . . . ]”). 
258. See, e.g., Xin Zhang, et al., Derivation of Human Embryonic Stem Cells 
from Developing and Arrested Embryos, 24 STEM CELLS 2669, 2671, 2672 
(2006). 
259. Thus, the text of Dickey-Wicker might read: “(a) None of the funds made 
available in this Act may be used for: (1) the creation of a viable human 
embryo or embryos for research purposes; or (2) research in which a viable 
human embryo or embryos are destroyed, discarded, or knowingly 
subjected to risk of injury or death greater than that allowed for research 
under 45 CFR 36.204(b) and section 498(b) of the Public Health Service 
Act (42 U.S.C. 289g(b)). (b) For the purposes of this section, the term 
“human embryo or embryos” includes any diploid organism, not protected 
as a human subject under 45 CFR 46 as of the date of the enactment of 
this Act, that is derived by fertilization, parthenogenesis, cloning, or any 
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Amending the statutory language to only encompass those embryos 
with propensity to develop into a fully-grown human (subsection (a)(1), 
(2)) may be more politically suitable and expedient, as permitting 
nonviable embryo modification only could be more palatable to pro-life 
politicians. This would unambiguously carve out an exception for 
researchers to use federal support in using TGE on ‘dead’ embryos. The 
second modification adds the qualifying word ‘diploid’ to the definition 
of “human embryo or embryos,” which would carve out an exception 
for tripronuclear embryos, and other embryos having an abnormal 
gamete copy number.260 The addition of this qualifier opens the door, if 
only a crack, to TGE research on embryos. This crack may be just 
enough, however, to empower American scientists to begin to close the 
knowledge gap that is emerging, as other nations entertain and embrace 
these controversial research proposals. 
Because an outright repeal of Dickey-Wicker is unlikely, certain 
research proposals would be rejected out-of-hand. Take Dr. Niakan’s 
study (discussed below in Section III.B), for example: her work focuses 
on genes involved in organismal development and why pregnancies 
terminate.261 This project would clearly be prohibited from being 
federally funded under the present-day Dickey-Wicker262 language, since 
the embryos are destroyed at the end of the experiment.263 Under a 
hypothetical revision (further qualifying “human embryo” by adding 
the word “viable”), work like Dr. Niakan’s would probably still be 
prohibited from receiving federal funds, since her work is being done 
with viable embryos. Some may argue that modifying an existing 
embryo meets the definition of “the creation of a [new] human 
embryo.”264 But the argument could also be made that introducing 
synthetic changes (or, alternatively, animal copies of the gene/mutation 
of interest) result in the creation of something novel, and not quite a 
human embryo.265 This argument, however, is fraught with peril: if 
 
other means from one or more human gametes or human diploid cells 
(emphasis added).” 
260. This may include monopronuclear (1PN) or polypronuclear ( 4PN) zy-
gotes. See, e.g., Yoshiteru Kai, et al., Diagnosis of Abnormal Human 
Fertilization Status Based on Pronuclear Origin and/or Centrosome 
Number, 32 J. ASSISTED REPROD. GENETICS 1589, 1589 (2015). 
261. Callaway, supra note 40. 
262. H.R. 2880, 104th Cong. § 128 (1996). 
263. Id. 
264. H.R. 2880, 104th Cong. § 128 (1996). 
265. Our legal system recognizes that a substantially altered biologic is 
regarded as something substantively different from the source material. 
See, e.g., Diamond v. Chakrabarty, 447 U.S. 303, 317-18 (1980). The 
United States Patent and Trademark Office (“USPTO”) affords patent 
protection to modified biologics, including cell lines. See, e.g., U.S. Patent 
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today we justify enabling research that modifies an embryo by claiming 
that the end product is no longer a human embryo, we prospectively 
set ourselves up for a legal morass if the day ever came that these so-
modified embryos were to be brought to term. Would a newborn, 
perceptively human but borne of embryonic modification, be considered 
something other than human? Would that newborn be afforded the 
same rights and protections as any other baby? Instinctively, we would 
say ‘yes,’ but preemptively categorizing its embryonic state as 
something other than a human embryo would clearly carry with it its 
own set of legal risks. 
D. Proposed ad hoc Committee Solution 
If embryonic research using TGE were putatively allowed, by either 
legislative or administrative action, it would be necessary to set clear 
and unambiguous ethical standards. One possibility of providing first-
blush ethical oversight would be to expand the regulatory power to two 
ad hoc committees: a governmental Inter-Departmental Advisory 
Committee, as well as a Citizens’ Advisory Committee. Both Inter-
Department Advisory Committees266 and Citizens’ Advisory  
No. 4,438,032 (filed Jan. 6, 1983). More relevantly, the United States 
Supreme Court in Ass’n. for Molecular Pathology v. Myriad Genetics 
distinguished between naturally occurring DNA sequences, which are 
ineligible for patent protection, and synthetic creations (“complimentary-
DNA or cDNA”), which are patent-eligible. Ass’n for Molecular Pathology 
v. Myriad Genetics, 133 S.Ct. 2107, 2119 (2013). Importantly, the Court 
held that the “creation of a cDNA sequence from mRNA results in an 
exons-only molecule that is not naturally occurring [emphasis added].” Id. 
at 2119. That the Court would recognize the patentability of a biologic 
that is not “naturally occurring” (Id. at 2111) and is “unquestionably 
[ . . . ] something new” (Id. at 2119) at the very least signals a distinction 
between organic matter found in nature and synthetically modified or 
altered matter. The CRISPR/Cas9 technology has been found by the U.S. 
Patent Trial and Appeal Board (“PTAB”) to be patentable subject 
matter. The Broad Institute, Inc. v. The Regents of the Univ. of Cal., No. 
106,048 (P.T.A.B. Feb. 15, 2017), 1-51, at 49 (holding for The Broad 
Institute over Univ. of California’s claim of patent interference; Univ. of 
California has appealed this decision to the U.S. Court of Appeals for the 
Federal Circuit. See also Jon Cohen, Ding, Ding, Ding! CRISPR Patent 
Fight Enters Next Round, SCIENCE NEWS (Jul. 26, 2017, 9:00 AM)). 
Inevitably, inventive products including TGE-modified human embryos 
will be claimed by inventors in applications to U.S. Patent and Trademark 
Office (“USPTO”) for patent protection. Under the Myriad framework, 
such constructs may be patent-eligible, as TGE-modified embryos are not 
“naturally occurring” and are “something new.” Myriad Genetics, 133 
S.Ct at 2111, 2119. Does this intellectual property definition distinguish 
TGE-modified human embryos as something different than naturally-
occurring “human embryos” under Dickey-Wicker?265. It remains a 
close question. 
266. See, e.g., Federal Interagency Committee on Indoor Air Quality (IAQ), 
U.S. ENVTL. PROTECTION COMMISSION, https://www.epa.gov/indoor-air-
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Committees267 have been developed for other purposes, when the issues 
presented are amenable to varied opinions and forethought. The NIH 
Director would have the authority (through the HHS Secretary and, 
ultimately, the President) to establish the two Advisory Committees, 
under 42 U.S.C. § 282(b)(16)268 and the Federal Advisory Committee 
Act of 1972.269 The purpose of these Advisory Committees would be to 
address the questions: “[w]hat embryonic TGE research deserves 
priority?” and “What are the ethical limits to such research?” These 
committees could weigh various factors such as which genetic disorders 
warrant priority over others270 or whether and how much animal model 
data would be required for a TGE-directed gene transfer. More than 
likely, HHS would spearhead the development of these committees 
through the Administrative Procedures Act’s rule-making process.271 
The committees might adopt a bicameral approach, such that each 
committee convene individually to draft its recommendations, then 
reconcile the two before issuing a final report. 
 
quality-iaq/federal-interagency-committee-indoor-air-quality (last visited 
Jan. 2, 2018). Established by Congress in 1983, IAQ is co-chaired by the 
EPA, the Consumer Product Safety Commission, the Department of 
Energy, the National Institute for Occupational Safety and Health, and 
the Occupational Safety and Health Administration. 
267. See, e.g., Gerhard Peters & John T. Wooley, Richard M. Nixon: 
Statement Announcing the Creation of the Environmental Quality Council 
and the Citizens’ Advisory Committee on Environmental Quality, THE 
AMERICAN PRESIDENCY PROJECT, http://www.presidency.ucsb.edu/ws
/?pid=2077 (last visited Apr. 9, 2018) (established a 15-member 
committee to “examine the full range of variables which affect 
environmental quality.”); see also 42 U.S.C. §4345 (1970). 
268. This is the same authority by which the NIH Director could establish the 
RAC. See supra note 203. 
269. Federal Advisory Committee Act of 1972, 5 U.S.C. App. §§1-16. 
Specifically, at § 7(a) established “[ . . . ] a Committee Management 
Secretariat, which shall be responsible for all matters relating to advisory 
committees. [ . . . ]” and § 9(a) “No advisory committee shall be 
established unless such establishment is – [ . . . ] (2) determined as a 
matter of formal record, by the head of the agency involved after 
consultation with the Administrator [of General Services], with timely 
notice published in the Federal Register, to be in the public interest in 
connection with the performance of duties imposed on that agency by 
law” (emphasis added). 
270. For example, single gene and more commonly prevalent disorders (e.g., 
monogenic, or single-gene, disorders which are most common, like cystic 
fibrosis, may warrant higher priority and, thus, greater fund accessibility). 
See e.g., Genes and Human Disease, WORLD HEALTH ORG., http://www.
who.int/genomics/public/geneticdiseases/en/index2.html (last visited 
Mar. 1, 2018). 
271. See 5 U.S.C. § 553 (1966). 
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The first tier, an inter-Department Advisory Committee might 
include representatives from relevant Independent Agencies and 
Executive Agencies including NIH, FDA, the National Science 
Foundation (“NSF”), the Department of Defense, and the Department 
of Agriculture (“USDA”).272 The Departments and Agencies might 
designate an appropriate employee of the Department or Agency versed 
in the scientific terminology to facilitate obtaining a swift, but 
deliberate decision on a particular grant proposal. Hypothetically, each 
Department/Agency listed above would be included, making for at least 
a 5-member committee. The ‘Citizens’ Advisory Committee,’ could be 
styled much like an IRB. Significantly, IRB membership requires that 
members have “varying backgrounds to promote complete and 
adequate review of research activities commonly conducted by the 
institution . . . ” including “at least one member whose primary 
concerns are in nonscientific areas . . . [and] at least one member who 
is not otherwise affiliated with the institution . . . ”273 A prototypical 
Committee might consist of: 
(1) at least one Member or Elected Fellow of the American 
Association for the Advancement of the Sciences (AAAS), 
preferably with expertise in the life sciences; 
(2) at least one Member of the American Medical Association (a 
licensed medical doctor, for example); 
(3) at least one Member of The National Academy of Sciences; 
(4) at least one Member of The National Academy of Medicine; 
and 
(5) at least one member whose primary concerns are in 
nonscientific areas (much like the IRB). 
One would argue that a spiritual, religious, or otherwise “pro-life” 
voice should be a part of the process. Such a voice would fit into group 
(3) in the hypothetical example above. This additional layer of scrutiny, 
while cumbersome at first blush, nevertheless imparts a deserved degree 
of gravity to the ultimate decision of whether or not to finance a given 
research proposal with taxpayer dollars. Whatever the system might 
look like in the end, it is absolutely critical that dissenting opinions 
against such projects receive a fair hearing. 
 
272. Possibly, if plant or animal genetic material were to be used in conjunction 
with the research on embryos. 
273. IRB Membership Rule, 45 C.F.R. § 46.107 (2010). 
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Conclusion 
Targeted Genomic Editing is and will remain a controversial 
subject, especially as applied to humans and human embryos. The 
ethical questions are hard but, as President Kennedy said, that is 
precisely why we should choose to accept such a challenge.274 In the 
same spirit as how in the industrial revolution we harvested coal to fuel 
factories, which mass produced the modern conveniences that enhanced 
the lives of so many, the genomic revolution has arrived. Directed 
biological evolution is no longer mere science fiction. If TGE—through 
CRISPR-Cas9 or its possible future successor technologies—provides 
humanity with a safe and effective means of command over the genetic 
sequence, ethical and moral questions abound; this is undeniable. Is it 
right to manipulate human embryos, considering that we have been 
legally manipulating embryos for decades (emergency contraception, 
abortion, IVF). Should we be playing God or have we already crossed 
the Rubicon? Consider also that the entire genome is up for grabs now, 
and the drive to achieve human enhancement will be as insatiable as 
for healing the sick. Private donors are free to fund whichever 
laboratory or project they wish. The public benefit has already deemed 
scientific research worthy of taxpayer support—through it we have a 
robust, diverse, largely collaborative (at home and abroad) manufactory 
of knowledge that can save lives and make them better. If TGE lives 
up to its realistic potential, genetic disease as we know it could cease 
to be. Prospective mothers may never again be forced to face the 
impossible situation of choosing to abort a pregnancy for fetal health 
reasons—a win for the pro-life movement. 
Epilogue 
We knew that we had created a new means of warfare, and the 
question as to what nation, to what victorious nation we were willing 
to entrust this brainchild of ours was a moral decision more than 
anything else. We wanted to see the world spared another conflict 
such as Germany had just been through, and we felt that only by 
surrendering such a weapon to people who are guided by the Bible 
could such an assurance to the world be best secured. 
-Wernher von Braun275 
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History has shown us that, where the national interest is sufficiently 
compelling, it is worse to do nothing than act in a manner which, in 
hindsight, could be seen as morally questionable. In the quest for 
technological supremacy, the ends tend to justify the means. On July 
20, 1969, American astronauts Neil Armstrong and Buzz Aldrin became 
the first humans to walk the surface of the moon.276 The Apollo 11 
mission was a success and, for all intents and purposes, the United 
States had won the Space Race. The United States and NASA had 
fulfilled the goal articulated by President Kennedy more than seven 
years prior, and more than four months ahead of the December 31, 1969 
deadline. The Saturn V rocket, which enabled the Apollo 11, was a joint 
project between NASA and the Douglas Aircraft Company, and was 
developed at the Marshall Space Flight Center in Huntsville, 
Alabama.277 The first director of the Marshall Center was Wernher von 
Braun.278 Dr. von Braun was one of the preeminent aerospace engineers 
and physicists of the 20th century.279 He was also a member of the Nazi 
Party,280 and was recruited to the Schutzstaffel (SS) in 1940. 281 His work 
proved instrumental in the development of the German V-2 rocket in 
1942 and revolutionized modern warfare.282 In 1944, he and about 125 
other prominent German scientists were recruited to the United States 
under Project Paperclip.283 He spent the next twenty-eight years serving 
the United States, and was instrumental in the nation’s development 
of rocketry and the Space Program. Viewed through the lens of history, 
it would be easy to judge the actions of our forbearers harshly. 
Colluding with Nazis?284 Unacceptable! But the national interest  
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ww.nasa.gov/mission_pages/apollo/missions/apollo11.html. 
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demanded it. Rocketry was a game changer, both militarily and with 
respect to space exploration, to “slip[] the surly bonds of Earth and 
dance[] the skies on laughter-silvered wings . . . ”285 To let the 
intellectual capital, epitomized by von Braun and others, be 
extinguished was an unacceptable loss to the United States. Instead, 
Project Paperclip snatched up this intellectual capital and put it to use, 
and the results speak for themselves. To have done nothing? That would 
have been unacceptable. It was true then, and remains true today. 
 
285. John Gillespie Magee, Jr., High Flight, available at http://www.davidpbr
own.co.uk/poetry/john-magee.html. 
